



## Clinical trial results:

**A Phase I/II study to assess the safety and immunogenicity of recMAGE-A3+AS15 cancer immunotherapeutic given as adjuvant therapy, with or without standard adjuvant chemo(-radio)therapy, to patients with MAGE A3-positive Non-Small Cell Lung Cancer (stage IB, II or III).**

### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2006-004777-10 |
| Trial protocol           | GB BE DE FR IT |
| Global end of trial date | 08 August 2013 |

### Results information

|                                |              |
|--------------------------------|--------------|
| Result version number          | v1           |
| This version publication date  | 11 May 2016  |
| First version publication date | 13 June 2015 |

### Trial information

#### Trial identification

|                       |        |
|-----------------------|--------|
| Sponsor protocol code | 107240 |
|-----------------------|--------|

#### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT00455572 |
| WHO universal trial number (UTN)   | -           |

Notes:

### Sponsors

|                              |   |
|------------------------------|---|
| Sponsor organisation name    | GlaxoSmithKline Biologicals   |
| Sponsor organisation address | Rue de l'Institut 89, Rixensart, Belgium, B-1330  |
| Public contact               | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com |
| Scientific contact           | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com |

Notes:

### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |                |
|--|----------------|
| Analysis stage                                       | Final          |
| Date of interim/final analysis                       | 05 June 2014   |
| Is this the analysis of the primary completion data? | Yes            |
| Primary completion date                              | 04 August 2013 |
| Global end of trial reached?                         | Yes            |
| Global end of trial date                             | 08 August 2013 |
| Was the trial ended prematurely?                     | Yes            |

Notes:

## General information about the trial

Main objective of the trial:

To assess the humoral and cellular immune response induced by recMAGE-A3+AS15 in patients with MAGE-A3-positive Non-Small Cell Lung Cancer (NSCLC). • To evaluate the safety of recMAGE-A3+AS15 in patients with MAGE-A3-positive NSCLC.

Protection of trial subjects:

All subjects were supervised after MAGE-A3 ASCI study product administration with appropriate medical treatment readily available. The MAGE-A3 ASCI study product was administered by qualified and trained personnel, and only to eligible patients who had no contraindications to any components of the MAGE-A3 ASCI study product. Subjects were followed up for occurrences of adverse events (AEs), including abnormal hematological and biochemical laboratory values, potential immune-mediated disorders (pIMDs and serious adverse events (SAEs) during the entire study period study. For subjects in all groups, if during the study the investigator was to come to consider any deviation from protocol-defined rules as to be in the patient's interest, then the investigator's decision was given priority over the rules. For Cohort 4, the chemo- and radiotherapy regimen was based upon the site's own standard procedures; again, the choice of treatment and any modification of this was to be governed by considerations of the patient's interest. Chemo- and radiotherapy may be administered in either sequence or concurrently. All patients who withdrew from the study and who had received any dose of study treatment were encouraged to be followed for assessment of possible toxicity. These patients were to be examined not less than 30 days and not more than 37 days after the last administration of MAGE-A3 ASCI study product.

Background therapy: -

Evidence for comparator: -

|   |             |
|---|-------------|
| Actual start date of recruitment                          | 11 May 2007 |
| Long term follow-up planned                               | No          |
| Independent data monitoring committee (IDMC) involvement? | No          |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                   |
|--------------------------------------|-------------------|
| Country: Number of subjects enrolled | United Kingdom: 8 |
| Country: Number of subjects enrolled | Belgium: 15       |
| Country: Number of subjects enrolled | France: 18        |
| Country: Number of subjects enrolled | Germany: 15       |
| Country: Number of subjects enrolled | Italy: 11         |
| Country: Number of subjects enrolled | Canada: 3         |
| Worldwide total number of subjects   | 70                |
| EEA total number of subjects         | 67                |

Notes:

| <b>Subjects enrolled per age group</b>    |    |
|---|----|
| In utero                                  | 0  |
| Preterm newborn - gestational age < 37 wk | 0  |
| Newborns (0-27 days)                      | 0  |
| Infants and toddlers (28 days-23 months)  | 0  |
| Children (2-11 years)                     | 0  |
| Adolescents (12-17 years)                 | 0  |
| Adults (18-64 years)                      | 35 |
| From 65 to 84 years                       | 35 |
| 85 years and over                         | 0  |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

70 patients were screened towards participation in the study. Out of these 70 patients, 67 were assessed as eligible for treatment and were administered the study MAGE-A3 ASCI study treatment.

### Period 1

|                              |                                       |
|------------------------------|---------------------------------------|
| Period 1 title               | Overall Study Period (overall period) |
| Is this the baseline period? | Yes                                   |
| Allocation method            | Non-randomised - controlled           |
| Blinding used                | Not blinded                           |

### Arms

|                              |                                   |
|------------------------------|-----------------------------------|
| Are arms mutually exclusive? | Yes                               |
| <b>Arm title</b>             | Chemotherapy + MAGE-A3 ASCI Group |

Arm description:

This group (Cohort 1 as per protocol summary) consisted in patients aged 18 years or more with completely resected stage IB, II or III tumors, who are due for chemotherapy, who received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product concurrently with cis-diaminedichloroplatine (CDDP) + vinorelbine [either Vinorelbine or Pierre Fabre's Navelbine] chemotherapy. The 8-dose course of MAGE-A3 ASCI study product was administered according to a 3-week intervals administration schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area. Patients were to receive up to 4 cycles of chemotherapy at 3-week intervals: 1 standard dose of CDDP and of vinorelbine intravenously on the first day of each cycle (starting at Week -1) and 1 standard dose of vinorelbine intravenously on Day 8 of each cycle, concomitantly with MAGE-A3 ASCI administration.

|  |  |
|--|--|
| Arm type                               | Experimental   |
| Investigational medicinal product name | recMAGE-A3 recombinant protein formulated in AS15 adjuvant |
| Investigational medicinal product code | recMAGE-A3 + AS15  |
| Other name                             | GSK1572932A; MAGE-A3 ASCI                                  |
| Pharmaceutical forms                   | Powder and solvent for suspension for injection            |
| Routes of administration               | Intramuscular use  |

Dosage and administration details:

Patients received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product. The 8-dose course of MAGE-A3 ASCI study product was to be administered according to a 3-week intervals administration schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area.

|                  |                                 |
|------------------|---------------------------------|
| <b>Arm title</b> | Chemotherapy/MAGE-A3 ASCI Group |
|------------------|---------------------------------|

Arm description:

This group (Cohort 2 as per protocol summary) consisted in patients aged 18 years or more with completely resected stage IB, II or III tumors who are due for chemotherapy, who received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product after receiving cis-diaminedichloroplatine (CDDP) + vinorelbine [either Vinorelbine or Pierre Fabre's Navelbine] chemotherapy. The 8-dose course of MAGE-A3 ASCI was administered according to a 3-week intervals schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area. Patients were to received at least 2 cycles of chemotherapy ,(1 standard dose of CDDP and of vinorelbine intravenously on the first day of each cycle and 1 dose of vinorelbine on Day 8 of each cycle), the last dose received to 4 weeks prior Dose 1 of MAGE-A3 ASCI. No additional chemotherapy was administered to patients from Week 0 onwards.

|          |              |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

|  |  |
|--|--|
| Investigational medicinal product name | recMAGE-A3 recombinant protein formulated in AS15 adjuvant |
| Investigational medicinal product code | recMAGE-A3 + AS15  |
| Other name                             | GSK1572932A; MAGE-A3 ASCI                                  |
| Pharmaceutical forms                   | Powder and solvent for suspension for injection            |
| Routes of administration               | Intramuscular use  |

**Dosage and administration details:**

Patients received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product. The 8-dose course of MAGE-A3 ASCI study product was to be administered according to a 3-week intervals administration schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area.

|                  |                    |
|------------------|--------------------|
| <b>Arm title</b> | MAGE-A3 ASCI Group |
|------------------|--------------------|

**Arm description:**

This group (Cohort 3 as per protocol summary) consisted in patients aged 18 years or more with completely resected stage IB, II or III tumors who are not due for cis-diaminedichloroplatine (CDDP) + vinorelbine chemotherapy, who received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product. The 8-dose course of MAGE-A3 ASCI study product was administered according to a 3-week intervals administration schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area. Patients were to have had their tumor resected at least 4 to 8 weeks prior to receiving Dose 1 of MAGE-A3 ASCI product and to receive no chemo-/radiotherapy during the entire duration of the study.

|  |  |
|--|--|
| Arm type                               | Experimental   |
| Investigational medicinal product name | recMAGE-A3 recombinant protein formulated in AS15 adjuvant |
| Investigational medicinal product code | recMAGE-A3 + AS15  |
| Other name                             | GSK1572932A; MAGE-A3 ASCI                                  |
| Pharmaceutical forms                   | Powder and solvent for suspension for injection            |
| Routes of administration               | Intramuscular use  |

**Dosage and administration details:**

Patients received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product. The 8-dose course of MAGE-A3 ASCI study product was to be administered according to a 3-week intervals administration schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area.

|                  |                                       |
|------------------|---------------------------------------|
| <b>Arm title</b> | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|------------------|---------------------------------------|

**Arm description:**

This group (Cohort 4 as per protocol summary) consisted in patients aged 18 years or more with unresectable stage III tumors following chemotherapy and radiotherapy who received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product. The 8-dose course of MAGE-A3 ASCI study product was to be administered according to a 3-week intervals administration schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area. Patients were to have received their last dose of chemotherapy (cis-diaminedichloroplatine [CDDP] + vinorelbine [either the generic Vinorelbine or Pierre Fabre's Navelbine]) and/or radiotherapy 2 to 6 weeks prior to receiving Dose 1 of MAGE-A3 ASCI product. No additional chemo-/radiotherapy was administered to patients in this cohort from Week 0 onwards.

|  |  |
|--|--|
| Arm type                               | Experimental   |
| Investigational medicinal product name | recMAGE-A3 recombinant protein formulated in AS15 adjuvant |
| Investigational medicinal product code | recMAGE-A3 + AS15  |
| Other name                             | GSK1572932A; MAGE-A3 ASCI                                  |
| Pharmaceutical forms                   | Powder and solvent for suspension for injection            |
| Routes of administration               | Intramuscular use  |

**Dosage and administration details:**

Patients received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product. The 8-dose course of MAGE-A3 ASCI study product was to be administered according to a 3-week intervals administration schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area.

| Number of subjects in period<br>1 <sup>[1]</sup>     | Chemotherapy +<br>MAGE-A3 ASCI<br>Group | Chemotherapy/MAG<br>E-A3 ASCI Group | MAGE-A3 ASCI<br>Group |
|--|---|-------------------------------------|-----------------------|
|  |   |                                     |                       |
| Started  | 19                                      | 18                                  | 18                    |
| Completed  | 15                                      | 14                                  | 8                     |
| Not completed  | 4                                       | 4                                   | 10                    |
| Adverse event, serious fatal                         | -                                       | -                                   | -                     |
| Adverse event, non-fatal                             | 1                                       | -                                   | 2                     |
| Recurrence/Disease Progression                       | -                                       | 4                                   | 6                     |
| Second cancer, reduced compliance<br>and comorbidity | 3                                       | -                                   | -                     |
| Other reasons  | -                                       | -                                   | 2                     |

| Number of subjects in period<br>1 <sup>[1]</sup>     | Chemo/radiotherapy<br>-MAGE-A3 ASCI<br>Group |
|--|--|
| Started  | 12   |
| Completed  | 8  |
| Not completed  | 4  |
| Adverse event, serious fatal                         | 1  |
| Adverse event, non-fatal                             | -  |
| Recurrence/Disease Progression                       | 3  |
| Second cancer, reduced compliance<br>and comorbidity | -  |
| Other reasons  | -  |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 70 patients were screened towards participation in the study. Out of these 70 patients, 67 were assessed as eligible for treatment and were administered the study MAGE-A3 ASCI study treatment.

## Baseline characteristics

### Reporting groups

|                       |                                   |
|-----------------------|-----------------------------------|
| Reporting group title | Chemotherapy + MAGE-A3 ASCI Group |
|-----------------------|-----------------------------------|

#### Reporting group description:

This group (Cohort 1 as per protocol summary) consisted in patients aged 18 years or more with completely resected stage IB, II or III tumors, who are due for chemotherapy, who received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product concurrently with cis-diaminedichloroplatine (CDDP) + vinorelbine [either Vinorelbine or Pierre Fabre's Navelbine] chemotherapy. The 8-dose course of MAGE-A3 ASCI study product was administered according to a 3-week intervals administration schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area. Patients were to receive up to 4 cycles of chemotherapy at 3-week intervals: 1 standard dose of CDDP and of vinorelbine intravenously on the first day of each cycle (starting at Week -1) and 1 standard dose of vinorelbine intravenously on Day 8 of each cycle, concomitantly with MAGE-A3 ASCI administration.

|                       |                                 |
|-----------------------|---------------------------------|
| Reporting group title | Chemotherapy/MAGE-A3 ASCI Group |
|-----------------------|---------------------------------|

#### Reporting group description:

This group (Cohort 2 as per protocol summary) consisted in patients aged 18 years or more with completely resected stage IB, II or III tumors who are due for chemotherapy, who received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product after receiving cis-diaminedichloroplatine (CDDP) + vinorelbine [either Vinorelbine or Pierre Fabre's Navelbine] chemotherapy. The 8-dose course of MAGE-A3 ASCI was administered according to a 3-week intervals schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area. Patients were to receive at least 2 cycles of chemotherapy, (1 standard dose of CDDP and of vinorelbine intravenously on the first day of each cycle and 1 dose of vinorelbine on Day 8 of each cycle), the last dose received to 4 weeks prior Dose 1 of MAGE-A3 ASCI. No additional chemotherapy was administered to patients from Week 0 onwards.

|                       |                    |
|-----------------------|--------------------|
| Reporting group title | MAGE-A3 ASCI Group |
|-----------------------|--------------------|

#### Reporting group description:

This group (Cohort 3 as per protocol summary) consisted in patients aged 18 years or more with completely resected stage IB, II or III tumors who are not due for cis-diaminedichloroplatine (CDDP) + vinorelbine chemotherapy, who received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product. The 8-dose course of MAGE-A3 ASCI study product was administered according to a 3-week intervals administration schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area. Patients were to have had their tumor resected at least 4 to 8 weeks prior to receiving Dose 1 of MAGE-A3 ASCI product and to receive no chemo-/radiotherapy during the entire duration of the study.

|                       |                                       |
|-----------------------|---------------------------------------|
| Reporting group title | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|-----------------------|---------------------------------------|

#### Reporting group description:

This group (Cohort 4 as per protocol summary) consisted in patients aged 18 years or more with unresectable stage III tumors following chemotherapy and radiotherapy who received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product. The 8-dose course of MAGE-A3 ASCI study product was to be administered according to a 3-week intervals administration schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area. Patients were to have received their last dose of chemotherapy (cis-diaminedichloroplatine [CDDP] + vinorelbine [either the generic Vinorelbine or Pierre Fabre's Navelbine]) and/or radiotherapy 2 to 6 weeks prior to receiving Dose 1 of MAGE-A3 ASCI product. No additional chemo-/radiotherapy was administered to patients in this cohort from Week 0 onwards.

| Reporting group values                             | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group |
|--|-----------------------------------|---------------------------------|--------------------|
| Number of subjects                                 | 19                                | 18                              | 18                 |
| Age categorical                                    |                                   |                                 |                    |
| Units: Subjects                                    |                                   |                                 |                    |
| In utero   |                                   |                                 |                    |
| Preterm newborn infants (gestational age < 37 wks) |                                   |                                 |                    |
| Newborns (0-27 days)                               |                                   |                                 |                    |

|   |                |                |                |
|---|----------------|----------------|----------------|
| Infants and toddlers (28 days-23 months)<br>Children (2-11 years)<br>Adolescents (12-17 years)<br>Adults (18-64 years)<br>From 65-84 years<br>85 years and over |                |                |                |
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation   | 58.7<br>± 10.3 | 60.6<br>± 6.37 | 67.1<br>± 9.81 |
| Gender categorical<br>Units: Subjects   |                |                |                |
| Female  | 14             | 15             | 16             |
| Male  | 5              | 3              | 2              |

| <b>Reporting group values</b>   | Chemo/radiotherapy<br>-MAGE-A3 ASCI<br>Group | Total |  |
|---|--|-------|--|
| Number of subjects  | 12   | 67    |  |
| Age categorical<br>Units: Subjects                                      |  |       |  |
| In utero  |  | 0     |  |
| Preterm newborn infants<br>(gestational age < 37 wks)                   |  | 0     |  |
| Newborns (0-27 days)  |  | 0     |  |
| Infants and toddlers (28 days-23 months)                                |  | 0     |  |
| Children (2-11 years)   |  | 0     |  |
| Adolescents (12-17 years)   |  | 0     |  |
| Adults (18-64 years)  |  | 0     |  |
| From 65-84 years  |  | 0     |  |
| 85 years and over   |  | 0     |  |
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | 59.9<br>± 7.33                               | -     |  |
| Gender categorical<br>Units: Subjects                                   |  |       |  |
| Female  | 7  | 52    |  |
| Male  | 5  | 15    |  |



## End points

### End points reporting groups

|                       |                                   |
|-----------------------|-----------------------------------|
| Reporting group title | Chemotherapy + MAGE-A3 ASCI Group |
|-----------------------|-----------------------------------|

#### Reporting group description:

This group (Cohort 1 as per protocol summary) consisted in patients aged 18 years or more with completely resected stage IB, II or III tumors, who are due for chemotherapy, who received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product concurrently with cis-diaminedichloroplatine (CDDP) + vinorelbine [either Vinorelbine or Pierre Fabre's Navelbine] chemotherapy. The 8-dose course of MAGE-A3 ASCI study product was administered according to a 3-week intervals administration schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area. Patients were to receive up to 4 cycles of chemotherapy at 3-week intervals: 1 standard dose of CDDP and of vinorelbine intravenously on the first day of each cycle (starting at Week -1) and 1 standard dose of vinorelbine intravenously on Day 8 of each cycle, concomitantly with MAGE-A3 ASCI administration.

|                       |                                 |
|-----------------------|---------------------------------|
| Reporting group title | Chemotherapy/MAGE-A3 ASCI Group |
|-----------------------|---------------------------------|

#### Reporting group description:

This group (Cohort 2 as per protocol summary) consisted in patients aged 18 years or more with completely resected stage IB, II or III tumors who are due for chemotherapy, who received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product after receiving cis-diaminedichloroplatine (CDDP) + vinorelbine [either Vinorelbine or Pierre Fabre's Navelbine chemotherapy. The 8-dose course of MAGE-A3 ASCI was administered according to a 3-week intervals schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area. Patients were to received at least 2 cycles of chemotherapy, (1 standard dose of CDDP and of vinorelbine intravenously on the first day of each cycle and 1 dose of vinorelbine on Day 8 of each cycle), the last dose received to 4 weeks prior Dose 1 of MAGE-A3 ASCI. No additional chemotherapy was administered to patients from Week 0 onwards.

|                       |                    |
|-----------------------|--------------------|
| Reporting group title | MAGE-A3 ASCI Group |
|-----------------------|--------------------|

#### Reporting group description:

This group (Cohort 3 as per protocol summary) consisted in patients aged 18 years or more with completely resected stage IB, II or III tumors who are not due for cis-diaminedichloroplatine (CDDP) + vinorelbine chemotherapy, who received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product. The 8-dose course of MAGE-A3 ASCI study product was administered according to a 3-week intervals administration schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area. Patients were to have had their tumor resected at least 4 to 8 weeks prior to receiving Dose 1 of MAGE-A3 ASCI product and to receive no chemo-/radiotherapy during the entire duration of the study.

|                       |                                       |
|-----------------------|---------------------------------------|
| Reporting group title | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|-----------------------|---------------------------------------|

#### Reporting group description:

This group (Cohort 4 as per protocol summary) consisted in patients aged 18 years or more with unresectable stage III tumors following chemotherapy and radiotherapy who received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product. The 8-dose course of MAGE-A3 ASCI study product was to be administered according to a 3-week intervals administration schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area. Patients were to have received their last dose of chemotherapy (cis-diaminedichloroplatine [CDDP] + vinorelbine [either the generic Vinorelbine or Pierre Fabre's Navelbine]) and/or radiotherapy 2 to 6 weeks prior to receiving Dose 1 of MAGE-A3 ASCI product. No additional chemo-/radiotherapy was administered to patients in this cohort from Week 0 onwards.

### Primary: Number of subjects seropositive for anti-Melanoma AntiGen (MAGE)-A3 antibodies

|                 |   |
|-----------------|---|
| End point title | Number of subjects seropositive for anti-Melanoma AntiGen (MAGE)-A3 antibodies <sup>[1]</sup> |
|-----------------|---|

#### End point description:

A seropositive subject for anti-MAGE-A3 antibodies was a subject with anti-MAGE-A3 antibodies  $\geq$  the seropositivity cut-off of 27 Enzyme-linked immunosorbent assay (ELISA) units per millilitre (EL.U/mL). The W6 time point was only applicable to Chemotherapy + MAGE-A3 Group. The Study End (SE) time point is only applicable to the Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3

ASCI groups and the Study Early Termination (ET) time point is only applicable to the Chemo/radiotherapy-MAGE-A3 ASCI Group.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At Screening (SCR), At Weeks 6, 7, 13, 16, 19, 22 and 27 (W6, W7, W13, W16, W19, W22 and W27) and at Study End (SE) or Study Early Termination (ET)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values                  | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|-----------------------------------|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type                | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed       | 19                                | 18                              | 16                 | 12                                    |
| Units: Subjects                   |                                   |                                 |                    |                                       |
| Anti-MAGE-A3, SCR (N=19;18;16;12) | 1                                 | 4                               | 0                  | 1                                     |
| Anti-MAGE-A3, W6 (N= 13;0;0;0)    | 12                                | 0                               | 0                  | 0                                     |
| Anti-MAGE-A3, W7 (N=11;15;13;10)  | 11                                | 14                              | 13                 | 9                                     |
| Anti-MAGE-A3, W13 (N=12;15;12;9)  | 12                                | 15                              | 12                 | 9                                     |
| Anti-MAGE-A3, W16 (N=12;16;10;8)  | 12                                | 16                              | 10                 | 8                                     |
| Anti-MAGE-A3, W19 (N=13;14;11;8)  | 13                                | 14                              | 11                 | 8                                     |
| Anti-MAGE-A3, W22 (N=15;12;8;8)   | 15                                | 12                              | 8                  | 8                                     |
| Anti-MAGE-A3, W27 (N=15;13;9;7)   | 15                                | 13                              | 9                  | 7                                     |
| Anti-MAGE-A3, SE (N=2;4;4;0)      | 1                                 | 4                               | 4                  | 0                                     |
| Anti-MAGE-A3, ET (N=0;0;0;2)      | 0                                 | 0                               | 0                  | 2                                     |

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of humoral responders as regards anti-Melanoma AntiGen (MAGE)-A3 antibodies

|                 |   |
|-----------------|---|
| End point title | Number of humoral responders as regards anti-Melanoma AntiGen (MAGE)-A3 antibodies <sup>[2]</sup> |
|-----------------|---|

End point description:

A seropositive/seronegative subject for anti-MAGE-A3 antibodies was a subject with anti-MAGE-A3 antibodies  $\geq$ / $<$  the seropositivity cut-off of 27 Enzyme-linked immunosorbent assay (ELISA) units per millilitre (EL.U/mL). A humoral responder as regards anti-MAGE-A3 antibodies was defined as 1) for initially seronegative patients, a patient with post-administration Anti-MAGE-A3 antibody concentration  $\geq$  27 EL.U/mL; 2) for initially seropositive patients: post-administration antibody concentration  $\geq$  2 fold the pre-vaccination antibody concentration.. The Week 6 time point was only applicable to Chemotherapy + MAGE-A3 Group. The SE time point is only applicable to the Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups and the ET time point is only applicable to the Chemo/radiotherapy-MAGE-A3 ASCI Group.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At Weeks 6, 7, 13, 16, 19, 22 and 27 (W6, W7, W13, W16, W19, W22 and W27) and at Study End (SE) or Study Early termination (ET)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values                 | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|----------------------------------|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type               | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed      | 15                                | 16                              | 12                 | 10                                    |
| Units: Subjects                  |                                   |                                 |                    |                                       |
| Anti-MAGE-A3, W6 (N=13;0;0;0)    | 12                                | 0                               | 0                  | 0                                     |
| Anti-MAGE-A3, W7 (N=11;15;12;10) | 11                                | 14                              | 12                 | 9                                     |
| Anti-MAGE-A3, W13 (N=12;15;10;9) | 12                                | 15                              | 10                 | 9                                     |
| Anti-MAGE-A3, W16 (N=12;16;8;8)  | 12                                | 16                              | 8                  | 8                                     |
| Anti-MAGE-A3, W19 (N=13;14;9;8)  | 13                                | 14                              | 9                  | 8                                     |
| Anti-MAGE-A3, W22 (N=15;12;8;8)  | 15                                | 12                              | 8                  | 8                                     |
| Anti-MAGE-A3, W27 (N=15;13;8;7)  | 15                                | 13                              | 8                  | 7                                     |
| Anti-MAGE-A3, SE (N=2;4;3;0)     | 1                                 | 4                               | 3                  | 0                                     |
| Anti-MAGE-A3, ET (N=0;0;0;2)     | 0                                 | 0                               | 0                  | 2                                     |

## Statistical analyses

No statistical analyses for this end point

## Primary: Concentrations for anti-Melanoma AntiGen (MAGE)-A3 antibodies

|                 |  |
|-----------------|--|
| End point title | Concentrations for anti-Melanoma AntiGen (MAGE)-A3 antibodies <sup>[3]</sup> |
|-----------------|--|

End point description:

The seropositivity cut-off of the assay was  $\geq 27$  Enzyme-linked immunosorbent assay (ELISA) units per millilitre (EL.U/mL). The Week 6 time point was only applicable to Chemotherapy + MAGE-A3 Group. The SE time point is only applicable to the Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups and the ET time point is only applicable to the Chemo/radiotherapy-MAGE-A3 ASCI Group.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At Screening (SCR), At Weeks 6, 7, 13, 16, 19, 22 and 27 (W6, W7, W13, W16, W19, W22 and W27) and at Study End (SE) or Study Early termination (ET)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values                         | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|--|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type                       | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed              | 19                                | 18                              | 16                 | 12                                    |
| Units: EL.U/mL                           |                                   |                                 |                    |                                       |
| geometric mean (confidence interval 95%) |                                   |                                 |                    |                                       |

|                                   |                           |                           |                           |                            |
|-----------------------------------|---------------------------|---------------------------|---------------------------|----------------------------|
| Anti-MAGE-A3, SCR (N=19;18;16;12) | 11 (9.5 to 12.8)          | 13.9 (10 to 19.2)         | 10.6 (9.3 to 12.1)        | 11.8 (9.2 to 15.1)         |
| Anti-MAGE-A3, W6 (N= 13;0;0;0)    | 330.5 (93.8 to 1164.1)    | 0 (0 to 0)                | 0 (0 to 0)                | 0 (0 to 0)                 |
| Anti-MAGE-A3, W7 (N=11;15;13;10)  | 438.8 (138.2 to 1393.9)   | 1171.1 (413.5 to 3316.6)  | 698 (370.2 to 1316)       | 975.3 (151.3 to 6288.8)    |
| Anti-MAGE-A3, W13 (N=12;15;12;9)  | 1711.7 (804 to 3644.6)    | 4336.1 (2971.4 to 6327.6) | 3051.3 (1808.9 to 5147.2) | 4927.5 (1147.8 to 21152.5) |
| Anti-MAGE-A3, W16 (N=12;16;10;8)  | 4250.4 (2244.4 to 8049.4) | 5433.6 (3704.4 to 7969.8) | 4360.1 (2484 to 7653.2)   | 5219 (1189.5 to 22898)     |
| Anti-MAGE-A3, W19 (N=13;14;11;8)  | 4828.8 (2955.6 to 7889.1) | 5217.6 (3888.8 to 7000.4) | 4298.1 (2802.1 to 6592.7) | 5557.9 (1138 to 27143.6)   |
| Anti-MAGE-A3, W22 (N=15;12;8;8)   | 4097.8 (2645.3 to 6347.8) | 4442.7 (3041.7 to 6489.1) | 4447.5 (2381.3 to 8306.4) | 8301.9 (5111 to 13484.9)   |
| Anti-MAGE-A3, W27 (N=15;13;9;7)   | 3591.2 (2199.9 to 5862.4) | 4339.9 (3305.4 to 5698.1) | 4213.4 (2386.1 to 7440.3) | 6406.5 (3594.9 to 11417.1) |
| Anti-MAGE-A3, SE (N=2;4;4;0)      | 16.7 (0 to 11599)         | 3155.1 (1306 to 7622.2)   | 2974.1 (429.5 to 20592.2) | 0 (0 to 0)                 |
| Anti-MAGE-A3, ET (N=0;0;0;2)      | 0 (0 to 0)                | 0 (0 to 0)                | 0 (0 to 0)                | 865.2 (227.9 to 3284.3)    |

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of subjects seropositive for anti-protein D (PD) antibodies

|                 |   |
|-----------------|---|
| End point title | Number of subjects seropositive for anti-protein D (PD) antibodies <sup>[4]</sup> |
|-----------------|---|

End point description:

A seropositive subject for anti-PD antibodies was a subject with anti-PD antibodies  $\geq$  the seropositivity cut-off of 100 Enzyme-linked immunosorbent assay (ELISA) units per millilitre (EL.U/mL). The Week 6 time point was only applicable to Chemotherapy + MAGE-A3 Group. The SE time point is only applicable to the Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups and the ET time point is only applicable to the Chemo/radiotherapy-MAGE-A3 ASCI Group.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At Screening (SCR), At Weeks 6, 7, 13, 16, 19, 22 and 27 (W6, W7, W13, W16, W19, W22 and W27) and at Study End (SE) or Study Early termination (ET)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values             | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|------------------------------|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type           | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed  | 19                                | 17                              | 17                 | 12                                    |
| Units: Subjects              |                                   |                                 |                    |                                       |
| Anti-PD, SCR (N=19;17;17;12) | 3                                 | 4                               | 6                  | 1                                     |
| Anti-PD, W6 (N=14;0;0;0)     | 14                                | 0                               | 0                  | 0                                     |

|                             |    |    |    |    |
|-----------------------------|----|----|----|----|
| Anti-PD, W7 (N=12;17;14;11) | 12 | 16 | 14 | 11 |
| Anti-PD, W13 (N=15;15;12;9) | 15 | 15 | 12 | 9  |
| Anti-PD, W16 (N=15;16;11;8) | 15 | 16 | 11 | 8  |
| Anti-PD, W19 (N=15;14;11;8) | 15 | 14 | 11 | 8  |
| Anti-PD, W22 (N=15;12;9;8)  | 15 | 12 | 9  | 8  |
| Anti-PD, W27 (N=15;13;9;7)  | 15 | 13 | 9  | 7  |
| Anti-PD, SE (N=2;4;4;0)     | 1  | 4  | 4  | 0  |
| Anti-PD, ET (N=0;0;0;2)     | 0  | 0  | 0  | 2  |

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of humoral responders as regards anti-protein D (PD) antibodies

|                 |   |
|-----------------|---|
| End point title | Number of humoral responders as regards anti-protein D (PD) antibodies <sup>[5]</sup> |
|-----------------|---|

End point description:

A seropositive/seronegative subject for anti-PD antibodies was a subject with anti-PD antibodies  $\geq$ / $<$  the seropositivity cut-off of 100 Enzyme-linked immunosorbent assay (ELISA) units per millilitre (EL.U/mL). A humoral responder as regards anti-PD antibodies was defined as 1) for initially seronegative patients, a patient with post-administration anti-PD antibody concentration  $\geq$  100 EL.U/mL; 2) for initially seropositive patients: post-administration antibody concentration  $\geq$  2 fold the pre-vaccination antibody concentration. The Week 6 time point was only applicable to Chemotherapy + MAGE-A3 Group. The SE time point is only applicable to the Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups and the ET time point is only applicable to the Chemo/radiotherapy-MAGE-A3 ASCI Group.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At Weeks 6, 7, 13, 16, 19, 22 and 27 (W6, W7, W13, W16, W19, W22 and W27) and at Study End (SE) or Study Early termination (ET)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values            | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|-----------------------------|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type          | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed | 15                                | 16                              | 13                 | 11                                    |
| Units: Subjects             |                                   |                                 |                    |                                       |
| Anti-PD, W6 (N=14;0;0;0)    | 14                                | 0                               | 0                  | 0                                     |
| Anti-PD, W7 (N=12;16;13;11) | 12                                | 15                              | 13                 | 11                                    |
| Anti-PD, W13 (N=15;14;11;9) | 15                                | 14                              | 11                 | 9                                     |
| Anti-PD, W16 (N=15;15;10;8) | 15                                | 15                              | 10                 | 8                                     |
| Anti-PD, W19 (N=15;13;10;7) | 15                                | 13                              | 10                 | 7                                     |
| Anti-PD, W22 (N=15;11;9;8)  | 15                                | 11                              | 9                  | 8                                     |
| Anti-PD, W27 (N=15;12;9;7)  | 15                                | 12                              | 9                  | 7                                     |
| Anti-PD, SE (N=2;4;3;0)     | 1                                 | 4                               | 3                  | 0                                     |
| Anti-PD, ET (N=0;0;0;2)     | 0                                 | 0                               | 0                  | 2                                     |

## Statistical analyses

No statistical analyses for this end point

### Primary: Concentrations for anti-protein D (PD) antibodies

|                 |  |
|-----------------|--|
| End point title | Concentrations for anti-protein D (PD) antibodies <sup>[6]</sup> |
|-----------------|--|

End point description:

The seropositivity cut-off of the assay was  $\geq 100$  Enzyme-linked immunosorbent assay (ELISA) units per millilitre (EL.U/mL). The Week 6 time point was only applicable to Chemotherapy + MAGE-A3 Group. The SE time point is only applicable to the Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups and the ET time point is only applicable to the Chemo/radiotherapy-MAGE-A3 ASCI Group.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At Screening (SCR), At Weeks 6, 7, 13, 16, 19, 22 and 27 (W6, W7, W13, W16, W19, W22 and W27) and at Study End (SE) or Study Early termination (ET)

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values                         | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group           | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|--|-----------------------------------|---------------------------------|------------------------------|---------------------------------------|
| Subject group type                       | Reporting group                   | Reporting group                 | Reporting group              | Reporting group                       |
| Number of subjects analysed              | 19                                | 17                              | 17                           | 12                                    |
| Units: EL.U/mL                           |                                   |                                 |                              |                                       |
| geometric mean (confidence interval 95%) |                                   |                                 |                              |                                       |
| Anti-PD, SCR (N=19;17;17;12)             | 65.9 (47.7 to 91.1)               | 68.2 (49.5 to 94.1)             | 95.5 (51.2 to 177.9)         | 53.4 (46.2 to 61.7)                   |
| Anti-PD, W6 (N=14;0;0;0)                 | 5126.7 (2628.8 to 9998)           | 0 (0 to 0)                      | 0 (0 to 0)                   | 0 (0 to 0)                            |
| Anti-PD, W7 (N=12;17;14;11)              | 5876.6 (2883.1 to 11978.4)        | 5871.1 (2309.1 to 14928.1)      | 6602.4 (2562.9 to 17008.8)   | 5393 (1649.1 to 17635.9)              |
| Anti-PD, W13 (N=15;15;12;9)              | 12842.6 (8672.1 to 19018.6)       | 16939.9 (9795.5 to 29295.4)     | 16165.9 (7282.9 to 35883.6)  | 13156.1 (6284.7 to 27540.5)           |
| Anti-PD, W16 (N=15;16;11;8)              | 17930.8 (12187.9 to 26379.8)      | 18029.7 (10977.9 to 29611.4)    | 22195.2 (9535.6 to 51662.1)  | 13226.5 (8515.5 to 20543.7)           |
| Anti-PD, W19 (N=15;14;11;8)              | 19471.8 (12865.4 to 29470.6)      | 17596.2 (11081.5 to 27940.7)    | 23456 (11664.4 to 47168)     | 15897.8 (9817.5 to 25743.7)           |
| Anti-PD, W22 (N=15;12;9;8)               | 19050.7 (12332.1 to 29429.6)      | 18349.4 (10737.7 to 31356.7)    | 27568.7 (10652.2 to 71349.7) | 16729.1 (10358 to 27018.9)            |
| Anti-PD, W27 (N=15;13;9;7)               | 16698.6 (10475 to 26619.7)        | 14190.5 (9343.3 to 21552.4)     | 27919.6 (13083.6 to 59578.7) | 13906.9 (8197.6 to 23592.3)           |

|                         |                       |                             |                             |                        |
|-------------------------|-----------------------|-----------------------------|-----------------------------|------------------------|
| Anti-PD, SE (N=2;4;4;0) | 231.8 (0 to 67660000) | 10620.8 (7991.3 to 14115.6) | 11438.9 (2879.3 to 45444.1) | 0 (0 to 0)             |
| Anti-PD, ET (N=0;0;0;2) | 0 (0 to 0)            | 0 (0 to 0)                  | 0 (0 to 0)                  | 8836.1 (0 to 28094000) |

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of patients seropositive as regards MAGE-A3 Cluster of Differentiation (CD)4 T-cell immunogenicity

|                 |  |
|-----------------|--|
| End point title | Number of patients seropositive as regards MAGE-A3 Cluster of Differentiation (CD)4 T-cell immunogenicity <sup>[7]</sup> |
|-----------------|--|

End point description:

A patient seropositive as regards MAGE-A3 CD4 T-cell immunogenicity was defined as a patient with geometric mean ratios (GMRs) between stimulated and unstimulated PBMC in a multiwell assay for the percentage of interferon (IFN)- and tumor necrosis factor (TNF)- double positive CD4 T-cells responding to MAGE-A3 overlapping peptide stimulation (IFN-g+TNF-aDble+ CD4)  $\geq$  the 8.4% seropositivity cut-off. The SE time point is only applicable to the Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups and the ET time point is only applicable to the Chemo/radiotherapy-MAGE-A3 ASCI Group.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At screening (SCR), at Weeks 13 and 27 (W13 and W27), and at Study End (SE) or Study Early termination (ET)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values                         | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|--|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type                       | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed              | 14                                | 17                              | 11                 | 8                                     |
| Units: Subjects                          |                                   |                                 |                    |                                       |
| IFN-g+TNF-aDble+ CD4, SCR (N=13;17;11;8) | 3                                 | 1                               | 0                  | 1                                     |
| IFN-g+TNF-aDble+ CD4, W13 (N=12;13;8;8)  | 7                                 | 4                               | 2                  | 5                                     |
| IFN-g+TNF-aDble+ CD4, W27 (N=14;13;6;7)  | 9                                 | 4                               | 4                  | 6                                     |
| IFN-g+TNF-aDble+ CD4, SE (N=2;1;1;0)     | 0                                 | 0                               | 0                  | 0                                     |
| IFN-g+TNF-aDble+ CD4, ET (N=0;0;0;2)     | 0                                 | 0                               | 0                  | 1                                     |

## Statistical analyses

No statistical analyses for this end point

**Primary: Number of patients responders as MAGE-A3 Cluster of Differentiation (CD)4 T-cell immunogenicity**

|                 |  |
|-----------------|--|
| End point title | Number of patients responders as MAGE-A3 Cluster of Differentiation (CD)4 T-cell immunogenicity <sup>[8]</sup> |
|-----------------|--|

## End point description:

A patient seropositive/seronegative for MAGE-A3 Cluster of Differentiation (CD)4 T-cell was a patient with geometric mean ratios (GMRs) for the percentage of IFN- and TNF- double positive CD4 T-cells responding to MAGE-A3 peptide stimulation (IFN-g+TNF-aDble+ CD4)  $\geq$  /< the 8.4% cut-off. A patient responder as MAGE-A3 CD4 T-cell was defined as follows: 1/for initially seronegative patients: post-administration antibody titer  $\geq$  8.4% for IFN-g+TNF-aDble+ CD4, or 2/for initially seropositive patients: post-administration antibody titer  $\geq$  4 fold the pre-vaccination antibody titer. The SE time point is only applicable to the Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups and the ET time point is only applicable to the Chemo/radiotherapy-MAGE-A3 ASCI Group. Please note that overlap was reported for W13 and W17, for 3 and 2 patients in the Chemotherapy + MAGE-A3 ASCI and Chemotherapy/MAGE-A3 ASCI groups, respectively, for whom a cellular response was found.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

## End point timeframe:

At Weeks 13 and 27 (W13 and W27), and at Study End (SE) or Study Early termination (ET)

## Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values                       | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|--|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type                     | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed            | 9                                 | 13                              | 6                  | 4                                     |
| Units: Subjects                        |                                   |                                 |                    |                                       |
| IFN-g+TNF-aDble+ CD4, W13 (N=7;12;6;4) | 4                                 | 3                               | 0                  | 2                                     |
| IFN-g+TNF-aDble+ CD4, W27 (N=9;13;4;4) | 3                                 | 3                               | 2                  | 4                                     |
| IFN-g+TNF-aDble+ CD4, SE (N=2;1;1;0)   | 0                                 | 0                               | 0                  | 0                                     |
| IFN-g+TNF-aDble+ CD4, ET (N=0;0;0;2)   | 0                                 | 0                               | 0                  | 1                                     |

**Statistical analyses**

No statistical analyses for this end point

**Primary: Number of patients seropositive as regards MAGE-A3 Cluster of Differentiation (CD)8 T-cell immunogenicity**

|                 |  |
|-----------------|--|
| End point title | Number of patients seropositive as regards MAGE-A3 Cluster of Differentiation (CD)8 T-cell immunogenicity <sup>[9]</sup> |
|-----------------|--|

## End point description:

A patient seropositive as regards MAGE-A3 CD8 T-cell immunogenicity was defined as a patient with geometric mean ratios (GMRs) between stimulated and unstimulated PBMC in a multiwell assay for the percentage of IFN- and TNF- double positive CD8 T-cells responding to MAGE-A3 overlapping peptide stimulation (IFN-g+TNF-aDble+ CD8)  $\geq$  the 3.2% seropositivity cut-off. The SE time point is only applicable to the Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups and the ET time point is only applicable to the Chemo/radiotherapy-MAGE-A3 ASCI Group.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|



End point timeframe:

At screening (SCR), at Weeks 13 and 27 (W13 and W27), and at Study End (SE) or Study Early termination (ET)

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values                         | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|--|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type                       | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed              | 14                                | 17                              | 11                 | 8                                     |
| Units: Subjects                          |                                   |                                 |                    |                                       |
| IFN-g+TNF-aDble+ CD8, SCR (N=13;17;11;8) | 0                                 | 2                               | 0                  | 0                                     |
| IFN-g+TNF-aDble+ CD8, W13 (N=12;13;8;8)  | 2                                 | 1                               | 2                  | 1                                     |
| IFN-g+TNF-aDble+ CD8, W27 (N=14;13;6;7)  | 1                                 | 3                               | 0                  | 1                                     |
| IFN-g+TNF-aDble+ CD8, SE (N=2;1;1;0)     | 1                                 | 0                               | 0                  | 0                                     |
| IFN-g+TNF-aDble+ CD8, ET (N=0;0;0;2)     | 0                                 | 0                               | 0                  | 0                                     |

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of patients responders as MAGE-A3 Cluster of Differentiation (CD)8 T-cell immunogenicity

|                 |   |
|-----------------|---|
| End point title | Number of patients responders as MAGE-A3 Cluster of Differentiation (CD)8 T-cell immunogenicity <sup>[10]</sup> |
|-----------------|---|

End point description:

A patient seropositive/seronegative for MAGE-A3 Cluster of Differentiation (CD)8 T-cell was a patient with geometric mean ratios (GMRs) for the percentage of IFN- and TNF- double positive CD8 T-cells responding to MAGE-A3 peptide stimulation (IFN-g+TNF-aDble+ CD8)  $\geq$  /< the 3.2% cut-off. A patient responder as MAGE-A3 CD8 T-cell was defined as follows: 1/for initially seronegative patients: post-administration antibody titer  $\geq$  3.2% for IFN-g+TNF-aDble+ CD8, or 2/for initially seropositive patients: post-administration antibody titer  $\geq$  4 fold the pre-vaccination antibody titer. The SE time point is only applicable to the Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups and the ET time point is only applicable to the Chemo/radiotherapy-MAGE-A3 ASCI Group.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At Weeks 13 and 27 (W13 and W27), and at Study End (SE) or Study Early termination (ET)

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values                       | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|--|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type                     | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed            | 9                                 | 13                              | 6                  | 4                                     |
| Units: Subjects                        |                                   |                                 |                    |                                       |
| IFN-g+TNF-aDble+ CD8, W13 (N=7;12;6;4) | 1                                 | 0                               | 0                  | 1                                     |
| IFN-g+TNF-aDble+ CD8, W27 (N=9;13;4;4) | 0                                 | 1                               | 0                  | 1                                     |
| IFN-g+TNF-aDble+ CD8, SE (N=2;1;1;0)   | 0                                 | 0                               | 0                  | 0                                     |
| IFN-g+TNF-aDble+ CD8, ET (N=0;0;0;2)   | 0                                 | 0                               | 0                  | 0                                     |

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of patients with abnormal haemoglobin laboratory values by maximum grade

|                 |   |
|-----------------|---|
| End point title | Number of patients with abnormal haemoglobin laboratory values by maximum grade <sup>[11]</sup> |
|-----------------|---|

End point description:

The status of each patient as regards haemoglobin (HAE) laboratory values at baseline and from screening up to Study End (SE) (Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups) or Study Early termination (ET) (Chemo/radiotherapy-MAGE-A3 ASCI Group) was collected and graded according to the Common Terminology Criteria (CTC) Adverse event terminology, version 3.0. By screening status, it was assessed whether the post-treatment values were above, below or in the normal range. Screening CTC grade statuses were Grade 0 (G0) and G1. Overall study post-treatment (PT) CTC grade statuses were, G0, G1, G2, G3, G4, G5 and Unknown (UNK).

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At screening (SCR) and throughout the entire study duration, from SCR to Study End (SE) or Study Early termination (ET)

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values            | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|-----------------------------|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type          | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed | 19                                | 18                              | 18                 | 12                                    |
| Units: Subjects             |                                   |                                 |                    |                                       |
| HAE - SCR G0; PT G1         | 7                                 | 1                               | 1                  | 0                                     |
| HAE - SCR G0; PT G2         | 0                                 | 0                               | 0                  | 0                                     |
| HAE - SCR G0; PT G3         | 0                                 | 0                               | 0                  | 0                                     |
| HAE - SCR G0; PT G4         | 0                                 | 0                               | 0                  | 0                                     |
| HAE - SCR G0; PT G5         | 0                                 | 0                               | 0                  | 0                                     |
| HAE - SCR G0; PT UNK        | 0                                 | 0                               | 4                  | 2                                     |
| HAE - SCR G1; PT G1         | 5                                 | 8                               | 5                  | 2                                     |
| HAE - SCR G1; PT G2         | 2                                 | 0                               | 0                  | 0                                     |

|                      |   |   |   |   |
|----------------------|---|---|---|---|
| HAE - SCR G1; PT G3  | 0 | 0 | 0 | 0 |
| HAE - SCR G1; PT G4  | 0 | 0 | 0 | 0 |
| HAE - SCR G1; PT G5  | 0 | 0 | 0 | 0 |
| HAE - SCR G1; PT UNK | 1 | 1 | 1 | 2 |

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of patients with abnormal leukocytes laboratory values by maximum grade

|                 |  |
|-----------------|--|
| End point title | Number of patients with abnormal leukocytes laboratory values by maximum grade <sup>[12]</sup> |
|-----------------|--|

End point description:

The status of each patient as regards leukocytes (LEU) laboratory values at baseline and from screening up to Study End (SE) (Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups) or Study Early termination (ET) (Chemo/radiotherapy-MAGE-A3 ASCI Group) was collected and graded according to the Common Terminology Criteria (CTC) Adverse event terminology, version 3.0. By screening status, it was assessed whether the post-treatment values were above, below or in the normal range. Screening CTC grade statuses were Grade 0 (G0) and G1. Overall study post-treatment (PT) CTC grade statuses were, G0, G1, G2, G3, G4, G5 and Unknown (UNK).

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At screening (SCR) and throughout the entire study duration, from SCR to Study End (SE) or Study Early termination (ET)

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values            | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|-----------------------------|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type          | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed | 19                                | 18                              | 18                 | 12                                    |
| Units: Subjects             |                                   |                                 |                    |                                       |
| LEU - SCR G0; PT G1         | 0                                 | 0                               | 1                  | 0                                     |
| LEU - SCR G0; PT G2         | 0                                 | 0                               | 0                  | 0                                     |
| LEU - SCR G0; PT G3         | 0                                 | 0                               | 0                  | 0                                     |
| LEU - SCR G0; PT G4         | 0                                 | 0                               | 0                  | 0                                     |
| LEU - SCR G0; PT G5         | 0                                 | 0                               | 0                  | 0                                     |
| LEU - SCR G0; PT UNK        | 1                                 | 1                               | 5                  | 4                                     |
| LEU - SCR G1; PT G1         | 0                                 | 0                               | 0                  | 2                                     |
| LEU - SCR G1; PT G2         | 0                                 | 0                               | 0                  | 0                                     |
| LEU - SCR G1; PT G3         | 0                                 | 0                               | 0                  | 0                                     |
| LEU - SCR G1; PT G4         | 0                                 | 0                               | 0                  | 0                                     |
| LEU - SCR G1; PT G5         | 0                                 | 0                               | 0                  | 0                                     |
| LEU - SCR G1; PT UNK        | 0                                 | 0                               | 0                  | 0                                     |

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of patients with abnormal lymphopenia laboratory values by maximum grade

|                 |   |
|-----------------|---|
| End point title | Number of patients with abnormal lymphopenia laboratory values by maximum grade <sup>[13]</sup> |
|-----------------|---|

End point description:

The status of each patient as regards lymphopenia (LYM) laboratory values at baseline and from screening up to Study End (SE) (Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups) or Study Early termination (ET) (Chemo/radiotherapy-MAGE-A3 ASCI Group) was collected and graded according to the Common Terminology Criteria (CTC) Adverse event terminology, version 3.0. By screening status, it was assessed whether the post-treatment values were above, below or in the normal range. Screening CTC grade statuses were Unknown (UNK), Grade 0 (G0), G1, G2, G3. Overall study post-treatment (PT) CTC grade statuses were, G0, G1, G2, G3, G4, G5 and Unknown (UNK).

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At screening (SCR) and throughout the entire study duration, from SCR to Study End (SE) or Study Early termination (ET)

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values            | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|-----------------------------|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type          | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed | 19                                | 18                              | 18                 | 12                                    |
| Units: Subjects             |                                   |                                 |                    |                                       |
| LYM - SCR UNK; PT G1        | 0                                 | 0                               | 0                  | 1                                     |
| LYM - SCR UNK; PT G2        | 0                                 | 0                               | 0                  | 0                                     |
| LYM - SCR UNK; PT G3        | 0                                 | 0                               | 0                  | 0                                     |
| LYM - SCR UNK; PT G4        | 0                                 | 0                               | 0                  | 0                                     |
| LYM - SCR UNK; PT G5        | 0                                 | 0                               | 0                  | 0                                     |
| LYM - SCR UNK; PT UNK       | 0                                 | 0                               | 0                  | 0                                     |
| LYM - SCR G0; PT G1         | 1                                 | 0                               | 2                  | 1                                     |
| LYM - SCR G0; PT G2         | 0                                 | 0                               | 0                  | 0                                     |
| LYM - SCR G0; PT G3         | 0                                 | 0                               | 0                  | 0                                     |
| LYM - SCR G0; PT G4         | 0                                 | 0                               | 0                  | 0                                     |
| LYM - SCR G0; PT G5         | 0                                 | 0                               | 0                  | 0                                     |
| LYM - SCR G0; PT UNK        | 1                                 | 1                               | 4                  | 0                                     |
| LYM - SCR G1; PT G1         | 0                                 | 1                               | 0                  | 0                                     |
| LYM - SCR G1; PT G2         | 0                                 | 0                               | 0                  | 0                                     |
| LYM - SCR G1; PT G3         | 0                                 | 0                               | 0                  | 0                                     |
| LYM - SCR G1; PT G4         | 0                                 | 0                               | 0                  | 0                                     |
| LYM - SCR G1; PT G5         | 0                                 | 0                               | 0                  | 0                                     |
| LYM - SCR G1; PT UNK        | 0                                 | 0                               | 1                  | 1                                     |
| LYM - SCR G2; PT G1         | 0                                 | 0                               | 0                  | 1                                     |
| LYM - SCR G2; PT G2         | 0                                 | 1                               | 1                  | 1                                     |
| LYM - SCR G2; PT G3         | 0                                 | 0                               | 0                  | 0                                     |
| LYM - SCR G2; PT G4         | 0                                 | 0                               | 0                  | 0                                     |
| LYM - SCR G2; PT G5         | 0                                 | 0                               | 0                  | 0                                     |

|                      |   |   |   |   |
|----------------------|---|---|---|---|
| LYM - SCR G2; PT UNK | 0 | 0 | 0 | 3 |
| LYM - SCR G3; PT G1  | 0 | 0 | 0 | 1 |
| LYM - SCR G3; PT G2  | 0 | 0 | 0 | 2 |
| LYM - SCR G3; PT G3  | 0 | 0 | 1 | 0 |
| LYM - SCR G3; PT G4  | 0 | 0 | 0 | 0 |
| LYM - SCR G3; PT G5  | 0 | 0 | 0 | 0 |
| LYM - SCR G3; PT UNK | 0 | 0 | 0 | 0 |

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of patients with abnormal neutrophils laboratory values by maximum grade

|                 |   |
|-----------------|---|
| End point title | Number of patients with abnormal neutrophils laboratory values by maximum grade <sup>[14]</sup> |
|-----------------|---|

End point description:

The status of each patient as regards neutrophils (NEU) laboratory values at baseline and from screening up to Study End (SE) (Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups) or Study Early termination (ET) (Chemo/radiotherapy-MAGE-A3 ASCI Group) was collected and graded according to the Common Terminology Criteria (CTC) Adverse event terminology, version 3.0. By screening status, it was assessed whether the post-treatment values were above, below or in the normal range. Screening CTC grade statuses were Grade 0 (G0) and G1. Overall study post-treatment (PT) CTC grade statuses were, G0, G1, G2, G3, G4, G5 and Unknown (UNK).

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At screening (SCR) and throughout the entire study duration, from SCR to Study End (SE) or Study Early termination (ET)

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values            | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|-----------------------------|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type          | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed | 19                                | 18                              | 18                 | 12                                    |
| Units: Subjects             |                                   |                                 |                    |                                       |
| NEU - SCR G0; PT G1         | 0                                 | 0                               | 1                  | 1                                     |
| NEU - SCR G0; PT G2         | 0                                 | 0                               | 0                  | 0                                     |
| NEU - SCR G0; PT G3         | 0                                 | 0                               | 0                  | 0                                     |
| NEU - SCR G0; PT G4         | 0                                 | 0                               | 0                  | 0                                     |
| NEU - SCR G0; PT G5         | 0                                 | 0                               | 0                  | 0                                     |
| NEU - SCR G0; PT UNK        | 1                                 | 0                               | 5                  | 4                                     |
| NEU - SCR G1; PT G1         | 0                                 | 0                               | 0                  | 0                                     |
| NEU - SCR G1; PT G2         | 0                                 | 0                               | 0                  | 0                                     |
| NEU - SCR G1; PT G3         | 0                                 | 0                               | 0                  | 0                                     |
| NEU - SCR G1; PT G4         | 0                                 | 0                               | 0                  | 0                                     |
| NEU - SCR G1; PT G5         | 0                                 | 0                               | 0                  | 0                                     |
| NEU - SCR G1; PT UNK        | 0                                 | 1                               | 0                  | 0                                     |

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of patients with abnormal platelets laboratory values by maximum grade

|                 |   |
|-----------------|---|
| End point title | Number of patients with abnormal platelets laboratory values by maximum grade <sup>[15]</sup> |
|-----------------|---|

End point description:

The status of each patient as regards platelets (PLA) laboratory values at baseline and from screening up to Study End (SE) (Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups) or Study Early termination (ET) (Chemo/radiotherapy-MAGE-A3 ASCI Group) was collected and graded according to the Common Terminology Criteria (CTC) Adverse event terminology, version 3.0. By screening status, it was assessed whether the post-treatment values were above, below or in the normal range. Screening CTC grade statuses were Grade 0 (G0) and G1. Overall study post-treatment (PT) CTC grade statuses were, G0, G1, G2, G3, G4, G5 and Unknown (UNK).

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At screening (SCR) and throughout the entire study duration, from SCR to Study End (SE) or Study Early termination (ET)

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values            | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|-----------------------------|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type          | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed | 19                                | 18                              | 18                 | 12                                    |
| Units: Subjects             |                                   |                                 |                    |                                       |
| PLA - SCR G0; PT G1         | 0                                 | 0                               | 0                  | 0                                     |
| PLA - SCR G0; PT G2         | 0                                 | 0                               | 0                  | 0                                     |
| PLA - SCR G0; PT G3         | 0                                 | 0                               | 0                  | 0                                     |
| PLA - SCR G0; PT G4         | 0                                 | 0                               | 0                  | 0                                     |
| PLA - SCR G0; PT G5         | 0                                 | 0                               | 0                  | 0                                     |
| PLA - SCR G0; PT UNK        | 1                                 | 1                               | 5                  | 3                                     |
| PLA - SCR G1; PT G1         | 0                                 | 0                               | 1                  | 1                                     |
| PLA - SCR G1; PT G2         | 0                                 | 0                               | 0                  | 0                                     |
| PLA - SCR G1; PT G3         | 0                                 | 0                               | 0                  | 0                                     |
| PLA - SCR G1; PT G4         | 0                                 | 0                               | 0                  | 0                                     |
| PLA - SCR G1; PT G5         | 0                                 | 0                               | 0                  | 0                                     |
| PLA - SCR G1; PT UNK        | 0                                 | 1                               | 0                  | 1                                     |

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of patients with adverse events (AEs) by maximum grade

|                 |   |
|-----------------|---|
| End point title | Number of patients with adverse events (AEs) by maximum grade <sup>[16]</sup> |
|-----------------|---|

End point description:

An AE was defined any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study. Patients' statuses as regards AEs reported from screening up to SE/ET was collected and graded according to the Common Terminology Criteria (CTC) AE terminology, version 3.0. The maximum grades reported were compiled. Grades compiled were Grade (G) 0, G1, G2, G3 and G4 for all groups as well as G5 for the Chemo/radiotherapy-MAGE-A3 ASCI Group only. The SE time point is only applicable to the Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups and the ET time point is only applicable to the Chemo/radiotherapy-MAGE-A3 ASCI Group.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Throughout the entire study duration, from screening (SCR) to Study End (SE) or Study Early termination (ET)

Notes:

[16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values            | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|-----------------------------|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type          | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed | 19                                | 18                              | 18                 | 12                                    |
| Units: Subjects             |                                   |                                 |                    |                                       |
| G1 AEs maximum              | 0                                 | 8                               | 1                  | 5                                     |
| G2 AEs maximum              | 3                                 | 8                               | 11                 | 5                                     |
| G3 AEs maximum              | 5                                 | 2                               | 3                  | 1                                     |
| G4 AEs maximum              | 11                                | 0                               | 2                  | 0                                     |
| G5 AEs maximum              | 0                                 | 0                               | 0                  | 1                                     |

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of patients with potential immune-mediated diseases (pIMDs)

|                 |  |
|-----------------|--|
| End point title | Number of patients with potential immune-mediated diseases (pIMDs) <sup>[17]</sup> |
|-----------------|--|

End point description:

pIMDs are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. The SE time point is only applicable to the Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups and the ET time point is only applicable to the Chemo/radiotherapy-MAGE-A3 ASCI Group.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Throughout the entire study duration, from screening (SCR) to Study End (SE) or Study Early termination (ET)

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values            | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|-----------------------------|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type          | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed | 19                                | 18                              | 18                 | 12                                    |
| Units: Subjects             |                                   |                                 |                    |                                       |
| pIMD(s)                     | 1                                 | 0                               | 0                  | 0                                     |

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of patients with unsolicited adverse events (AEs), irrespective of grade

|                 |   |
|-----------------|---|
| End point title | Number of patients with unsolicited adverse events (AEs), irrespective of grade <sup>[18]</sup> |
|-----------------|---|

End point description:

An AE was any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Within the 31-day follow-up period post study product administration.

Notes:

[18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values            | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|-----------------------------|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type          | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed | 19                                | 18                              | 18                 | 12                                    |
| Units: Subjects             |                                   |                                 |                    |                                       |
| Any AE                      | 19                                | 18                              | 17                 | 11                                    |

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of patients with serious adverse events (SAEs)

|                 |   |
|-----------------|---|
| End point title | Number of patients with serious adverse events (SAEs) <sup>[19]</sup> |
|-----------------|---|

End point description:

A SAE is any untoward medical occurrence that resulted in death, was life-threatening,



required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study subject, or was a Grade 4 AE according to the Common Terminology Criteria for Adverse Events, Version 3.0. Progression of disease or cancer recurrence were not reported as a SAE. However, if the progression of the underlying disease was greater than that which would normally be expected for the patient. If a causal relationship between treatment or protocol design/procedures and the disease progression/recurrence was assessed, the event was reported as SAE. Any new cancer (not related to the cancer under study) was reported as a SAE. The SE time point is only applicable to the Chemotherapy + MAGE-A3, Chemotherapy/MAGE-A3 ASCI and MAGE-A3 ASCI groups and the ET is only applicable to the Chemo/radiotherapy-MAGE-A3 ASCI Group.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Throughout the entire study duration, from screening (SCR) to Study End (SE) or Study Early termination (ET)

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values            | Chemotherapy + MAGE-A3 ASCI Group | Chemotherapy/MAGE-A3 ASCI Group | MAGE-A3 ASCI Group | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|-----------------------------|-----------------------------------|---------------------------------|--------------------|---------------------------------------|
| Subject group type          | Reporting group                   | Reporting group                 | Reporting group    | Reporting group                       |
| Number of subjects analysed | 19                                | 18                              | 18                 | 12                                    |
| Units: Subjects             |                                   |                                 |                    |                                       |
| Any SAE                     | 12                                | 0                               | 4                  | 3                                     |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

SAEs: From screening to study end/early termination; Unsolicited AEs: Within the 31-day follow-up period post study product administration.

Adverse event reporting additional description:

The occurrence of reported AEs (all/related) was not available and is encoded as equal to the number of subjects affected.

|                 |                |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 17.0 |
|--------------------|------|

### Reporting groups

|                       |                              |
|-----------------------|------------------------------|
| Reporting group title | Chemotherapy + MAGE-A3 Group |
|-----------------------|------------------------------|

Reporting group description:

This group (Cohort 1 as per protocol summary) consisted in patients aged 18 years or more with completely resected stage IB, II or III tumors, who are due for chemotherapy, who received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product concurrently with cis-diaminedichloroplatine (CDDP) + vinorelbine [either Vinorelbine® or Pierre Fabre's Navelbine®] chemotherapy. The 8-dose course of MAGE-A3 ASCI study product was administered according to a 3-week intervals administration schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area. Patients were to receive up to 4 cycles of chemotherapy at 3-week intervals: 1 standard dose of CDDP and of vinorelbine intravenously on the first day of each cycle (starting at Week -1) and 1 standard dose of vinorelbine intravenously on Day 8 of each cycle, concomitantly with MAGE-A3 ASCI administration.

|                       |                                 |
|-----------------------|---------------------------------|
| Reporting group title | Chemotherapy/MAGE-A3 ASCI Group |
|-----------------------|---------------------------------|

Reporting group description:

This group (Cohort 2 as per protocol summary) consisted in patients aged 18 years or more with completely resected stage IB, II or III tumors who are due for chemotherapy, who received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product after receiving cis-diaminedichloroplatine (CDDP) + vinorelbine [either Vinorelbine® or Pierre Fabre's Navelbine®] chemotherapy. The 8-dose course of MAGE-A3 ASCI was administered according to a 3-week intervals schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area. Patients were to receive at least 2 cycles of chemotherapy (1 standard dose of CDDP and of vinorelbine intravenously on the first day of each cycle and 1 dose of vinorelbine on Day 8 of each cycle), the last dose received to 4 weeks prior Dose 1 of MAGE-A3 ASCI. No additional chemotherapy was administered to patients from Week 0 onwards.

|                       |                    |
|-----------------------|--------------------|
| Reporting group title | MAGE-A3 ASCI Group |
|-----------------------|--------------------|

Reporting group description:

This group (Cohort 3 as per protocol summary) consisted in patients aged 18 years or more with completely resected stage IB, II or III tumors who are not due for cis-diaminedichloroplatine (CDDP) + vinorelbine chemotherapy, who received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product. The 8-dose course of MAGE-A3 ASCI study product was administered according to a 3-week intervals administration schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area. Patients were to have had their tumor resected at least 4 to 8 weeks prior to receiving Dose 1 of MAGE-A3 ASCI product and to receive no chemo-/radiotherapy during the entire duration of the study.

|                       |                                       |
|-----------------------|---------------------------------------|
| Reporting group title | Chemo/radiotherapy-MAGE-A3 ASCI Group |
|-----------------------|---------------------------------------|

Reporting group description:

This group (Cohort 4 as per protocol summary) consisted in patients aged 18 years or more with unresectable stage III tumors following chemotherapy and radiotherapy who received 8 doses of the GSK1572932A (or MAGE-A3 ASCI) study product. The 8-dose course of MAGE-A3 ASCI study product was to be administered according to a 3-week intervals administration schedule, at Weeks 0, 3, 6, 9, 12, 15, 18 and 21, intramuscularly in the deltoid or lateral region of the thigh, alternating left and right side, irrespective of the patient's body weight or area. Patients were to have received their last dose of chemotherapy (cis-diaminedichloroplatine [CDDP] + vinorelbine [either the generic Vinorelbine® or Pierre Fabre's Navelbine®]) and/or radiotherapy 2 to 6 weeks prior to receiving Dose 1 of MAGE-A3 ASCI product. No additional chemo-/radiotherapy was administered to patients in this cohort from Week 0 onwards.

| <b>Serious adverse events</b>                                       | <b>Chemotherapy +<br/>MAGE-A3 Group</b> | <b>Chemotherapy/MAG<br/>E-A3 ASCI Group</b> | <b>MAGE-A3 ASCI<br/>Group</b> |
|---|---|---|-------------------------------|
| Total subjects affected by serious adverse events                   |   |   |                               |
| subjects affected / exposed   | 12 / 19 (63.16%)                        | 0 / 18 (0.00%)                              | 4 / 18 (22.22%)               |
| number of deaths (all causes)                                       | 0                                       | 0   | 0                             |
| number of deaths resulting from adverse events                      |   |   |                               |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |   |   |                               |
| Malignant palate neoplasm   |   |   |                               |
| subjects affected / exposed   | 1 / 19 (5.26%)                          | 0 / 18 (0.00%)                              | 0 / 18 (0.00%)                |
| occurrences causally related to treatment / all                     | 0 / 1                                   | 0 / 0                                       | 0 / 0                         |
| deaths causally related to treatment / all                          | 0 / 0                                   | 0 / 0                                       | 0 / 0                         |
| Injury, poisoning and procedural complications                      |   |   |                               |
| Concussion  |   |   |                               |
| subjects affected / exposed   | 1 / 19 (5.26%)                          | 0 / 18 (0.00%)                              | 0 / 18 (0.00%)                |
| occurrences causally related to treatment / all                     | 0 / 1                                   | 0 / 0                                       | 0 / 0                         |
| deaths causally related to treatment / all                          | 0 / 0                                   | 0 / 0                                       | 0 / 0                         |
| Contusion   |   |   |                               |
| subjects affected / exposed   | 0 / 19 (0.00%)                          | 0 / 18 (0.00%)                              | 0 / 18 (0.00%)                |
| occurrences causally related to treatment / all                     | 0 / 0                                   | 0 / 0                                       | 0 / 0                         |
| deaths causally related to treatment / all                          | 0 / 0                                   | 0 / 0                                       | 0 / 0                         |
| Vascular disorders  |   |   |                               |
| Thrombosis  |   |   |                               |
| subjects affected / exposed   | 0 / 19 (0.00%)                          | 0 / 18 (0.00%)                              | 1 / 18 (5.56%)                |
| occurrences causally related to treatment / all                     | 0 / 0                                   | 0 / 0                                       | 0 / 1                         |
| deaths causally related to treatment / all                          | 0 / 0                                   | 0 / 0                                       | 0 / 0                         |
| Cardiac disorders   |   |   |                               |
| Cardiac failure   |   |   |                               |
| subjects affected / exposed   | 0 / 19 (0.00%)                          | 0 / 18 (0.00%)                              | 1 / 18 (5.56%)                |
| occurrences causally related to treatment / all                     | 0 / 0                                   | 0 / 0                                       | 0 / 1                         |
| deaths causally related to treatment / all                          | 0 / 0                                   | 0 / 0                                       | 0 / 0                         |
| Cardiac failure acute   |   |   |                               |

|  |                 |                |                |
|--|-----------------|----------------|----------------|
| subjects affected / exposed                          | 0 / 19 (0.00%)  | 0 / 18 (0.00%) | 1 / 18 (5.56%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0          |
| Blood and lymphatic system disorders                 |                 |                |                |
| Neutropenia  |                 |                |                |
| subjects affected / exposed                          | 6 / 19 (31.58%) | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 6           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0          |
| Febrile neutropenia                                  |                 |                |                |
| subjects affected / exposed                          | 5 / 19 (26.32%) | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 5           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0          |
| General disorders and administration site conditions |                 |                |                |
| Influenza like illness                               |                 |                |                |
| subjects affected / exposed                          | 1 / 19 (5.26%)  | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0          |
| Mucosal inflammation                                 |                 |                |                |
| subjects affected / exposed                          | 1 / 19 (5.26%)  | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0          |
| Pain   |                 |                |                |
| subjects affected / exposed                          | 1 / 19 (5.26%)  | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                           |                 |                |                |
| Nausea   |                 |                |                |
| subjects affected / exposed                          | 1 / 19 (5.26%)  | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders      |                 |                |                |
| Bronchitis chronic                                   |                 |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 1 / 19 (5.26%) | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pulmonary embolism                              |                |                |                |
| subjects affected / exposed                     | 1 / 19 (5.26%) | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Bronchial haemorrhage                           |                |                |                |
| subjects affected / exposed                     | 0 / 19 (0.00%) | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Hepatobiliary disorders                         |                |                |                |
| Hepatic failure                                 |                |                |                |
| subjects affected / exposed                     | 0 / 19 (0.00%) | 0 / 18 (0.00%) | 1 / 18 (5.56%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Skin and subcutaneous tissue disorders          |                |                |                |
| Urticaria chronic                               |                |                |                |
| subjects affected / exposed                     | 0 / 19 (0.00%) | 0 / 18 (0.00%) | 1 / 18 (5.56%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| Arthralgia                                      |                |                |                |
| subjects affected / exposed                     | 1 / 19 (5.26%) | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Pneumonia                                       |                |                |                |
| subjects affected / exposed                     | 1 / 19 (5.26%) | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

|                                    |  |  |  |
|------------------------------------|--|--|--|
| <b>Serious adverse events</b>      | Chemo/radiotherapy<br>-MAGE-A3 ASCI<br>Group |  |  |
| Total subjects affected by serious |  |  |  |

|   |                 |  |  |
|---|-----------------|--|--|
| adverse events  |                 |  |  |
| subjects affected / exposed   | 3 / 12 (25.00%) |  |  |
| number of deaths (all causes)                                       | 1               |  |  |
| number of deaths resulting from adverse events                      |                 |  |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                 |  |  |
| Malignant palate neoplasm   |                 |  |  |
| subjects affected / exposed   | 0 / 12 (0.00%)  |  |  |
| occurrences causally related to treatment / all                     | 0 / 0           |  |  |
| deaths causally related to treatment / all                          | 0 / 0           |  |  |
| Injury, poisoning and procedural complications                      |                 |  |  |
| Concussion  |                 |  |  |
| subjects affected / exposed   | 0 / 12 (0.00%)  |  |  |
| occurrences causally related to treatment / all                     | 0 / 0           |  |  |
| deaths causally related to treatment / all                          | 0 / 0           |  |  |
| Contusion   |                 |  |  |
| subjects affected / exposed   | 1 / 12 (8.33%)  |  |  |
| occurrences causally related to treatment / all                     | 0 / 1           |  |  |
| deaths causally related to treatment / all                          | 0 / 0           |  |  |
| Vascular disorders  |                 |  |  |
| Thrombosis  |                 |  |  |
| subjects affected / exposed   | 0 / 12 (0.00%)  |  |  |
| occurrences causally related to treatment / all                     | 0 / 0           |  |  |
| deaths causally related to treatment / all                          | 0 / 0           |  |  |
| Cardiac disorders   |                 |  |  |
| Cardiac failure   |                 |  |  |
| subjects affected / exposed   | 0 / 12 (0.00%)  |  |  |
| occurrences causally related to treatment / all                     | 0 / 0           |  |  |
| deaths causally related to treatment / all                          | 0 / 0           |  |  |
| Cardiac failure acute   |                 |  |  |
| subjects affected / exposed   | 0 / 12 (0.00%)  |  |  |
| occurrences causally related to treatment / all                     | 0 / 0           |  |  |
| deaths causally related to treatment / all                          | 0 / 0           |  |  |
| Blood and lymphatic system disorders                                |                 |  |  |
| Neutropenia   |                 |  |  |

|  |                |  |  |
|--|----------------|--|--|
| subjects affected / exposed                          | 0 / 12 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Febrile neutropenia                                  |                |  |  |
| subjects affected / exposed                          | 0 / 12 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| General disorders and administration site conditions |                |  |  |
| Influenza like illness                               |                |  |  |
| subjects affected / exposed                          | 0 / 12 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Mucosal inflammation                                 |                |  |  |
| subjects affected / exposed                          | 0 / 12 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Pain   |                |  |  |
| subjects affected / exposed                          | 0 / 12 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Gastrointestinal disorders                           |                |  |  |
| Nausea   |                |  |  |
| subjects affected / exposed                          | 0 / 12 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Respiratory, thoracic and mediastinal disorders      |                |  |  |
| Bronchitis chronic                                   |                |  |  |
| subjects affected / exposed                          | 0 / 12 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Pulmonary embolism                                   |                |  |  |

|   |                |  |  |
|---|----------------|--|--|
| subjects affected / exposed                     | 0 / 12 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Bronchial haemorrhage                           |                |  |  |
| subjects affected / exposed                     | 1 / 12 (8.33%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Hepatobiliary disorders                         |                |  |  |
| Hepatic failure                                 |                |  |  |
| subjects affected / exposed                     | 0 / 12 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Skin and subcutaneous tissue disorders          |                |  |  |
| Urticaria chronic                               |                |  |  |
| subjects affected / exposed                     | 0 / 12 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Musculoskeletal and connective tissue disorders |                |  |  |
| Arthralgia                                      |                |  |  |
| subjects affected / exposed                     | 0 / 12 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Infections and infestations                     |                |  |  |
| Pneumonia                                       |                |  |  |
| subjects affected / exposed                     | 1 / 12 (8.33%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                                   | Chemotherapy +<br>MAGE-A3 Group | Chemotherapy/MAG<br>E-A3 ASCI Group | MAGE-A3 ASCI<br>Group |
|---|---------------------------------|-------------------------------------|-----------------------|
| Total subjects affected by non-serious adverse events               |                                 |                                     |                       |
| subjects affected / exposed   | 19 / 19 (100.00%)               | 18 / 18 (100.00%)                   | 17 / 18 (94.44%)      |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                                 |                                     |                       |



|   |                     |                     |                     |
|---|---------------------|---------------------|---------------------|
| Malignant palate neoplasm<br>subjects affected / exposed<br>occurrences (all) | 1 / 19 (5.26%)<br>1 | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 |
| Vascular disorders  |                     |                     |                     |
| Arterial disorder<br>subjects affected / exposed<br>occurrences (all)         | 0 / 19 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 |
| Arteriosclerosis<br>subjects affected / exposed<br>occurrences (all)          | 1 / 19 (5.26%)<br>1 | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 |
| Haematoma<br>subjects affected / exposed<br>occurrences (all)                 | 1 / 19 (5.26%)<br>1 | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 |
| Hypertension<br>subjects affected / exposed<br>occurrences (all)              | 1 / 19 (5.26%)<br>1 | 0 / 18 (0.00%)<br>0 | 1 / 18 (5.56%)<br>1 |
| Orthostatic hypotension<br>subjects affected / exposed<br>occurrences (all)   | 1 / 19 (5.26%)<br>1 | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 |
| Peripheral coldness<br>subjects affected / exposed<br>occurrences (all)       | 0 / 19 (0.00%)<br>0 | 1 / 18 (5.56%)<br>1 | 0 / 18 (0.00%)<br>0 |
| Phlebitis<br>subjects affected / exposed<br>occurrences (all)                 | 1 / 19 (5.26%)<br>1 | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 |
| Phlebitis superficial<br>subjects affected / exposed<br>occurrences (all)     | 1 / 19 (5.26%)<br>1 | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 |
| Raynaud's phenomenon<br>subjects affected / exposed<br>occurrences (all)      | 1 / 19 (5.26%)<br>1 | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 |
| Thrombosis<br>subjects affected / exposed<br>occurrences (all)                | 0 / 19 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 1 / 18 (5.56%)<br>1 |
| General disorders and administration<br>site conditions                       |                     |                     |                     |

|  |                 |                 |                 |
|--|-----------------|-----------------|-----------------|
| Administration site pain                   |                 |                 |                 |
| subjects affected / exposed                | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                          | 1               | 0               | 0               |
| Administration site reaction               |                 |                 |                 |
| subjects affected / exposed                | 4 / 19 (21.05%) | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                          | 4               | 0               | 0               |
| Asthenia                                   |                 |                 |                 |
| subjects affected / exposed                | 7 / 19 (36.84%) | 0 / 18 (0.00%)  | 2 / 18 (11.11%) |
| occurrences (all)                          | 7               | 0               | 2               |
| Axillary pain                              |                 |                 |                 |
| subjects affected / exposed                | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 1 / 18 (5.56%)  |
| occurrences (all)                          | 0               | 0               | 1               |
| Chest pain                                 |                 |                 |                 |
| subjects affected / exposed                | 1 / 19 (5.26%)  | 1 / 18 (5.56%)  | 1 / 18 (5.56%)  |
| occurrences (all)                          | 1               | 1               | 1               |
| Chills                                     |                 |                 |                 |
| subjects affected / exposed                | 0 / 19 (0.00%)  | 4 / 18 (22.22%) | 3 / 18 (16.67%) |
| occurrences (all)                          | 0               | 4               | 3               |
| Fatigue                                    |                 |                 |                 |
| alternative assessment type:<br>Systematic |                 |                 |                 |
| subjects affected / exposed                | 5 / 19 (26.32%) | 5 / 18 (27.78%) | 3 / 18 (16.67%) |
| occurrences (all)                          | 5               | 5               | 3               |
| Gait disturbance                           |                 |                 |                 |
| subjects affected / exposed                | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                          | 1               | 0               | 0               |
| Hypothermia                                |                 |                 |                 |
| subjects affected / exposed                | 0 / 19 (0.00%)  | 1 / 18 (5.56%)  | 0 / 18 (0.00%)  |
| occurrences (all)                          | 0               | 1               | 0               |
| Influenza like illness                     |                 |                 |                 |
| subjects affected / exposed                | 2 / 19 (10.53%) | 1 / 18 (5.56%)  | 5 / 18 (27.78%) |
| occurrences (all)                          | 2               | 1               | 5               |
| Injection site coldness                    |                 |                 |                 |
| subjects affected / exposed                | 0 / 19 (0.00%)  | 1 / 18 (5.56%)  | 0 / 18 (0.00%)  |
| occurrences (all)                          | 0               | 1               | 0               |
| Injection site erythema                    |                 |                 |                 |

|                             |                  |                  |                  |
|-----------------------------|------------------|------------------|------------------|
| subjects affected / exposed | 0 / 19 (0.00%)   | 3 / 18 (16.67%)  | 2 / 18 (11.11%)  |
| occurrences (all)           | 0                | 3                | 2                |
| Injection site haematoma    |                  |                  |                  |
| subjects affected / exposed | 2 / 19 (10.53%)  | 0 / 18 (0.00%)   | 1 / 18 (5.56%)   |
| occurrences (all)           | 2                | 0                | 1                |
| Injection site inflammation |                  |                  |                  |
| subjects affected / exposed | 0 / 19 (0.00%)   | 0 / 18 (0.00%)   | 4 / 18 (22.22%)  |
| occurrences (all)           | 0                | 0                | 4                |
| Injection site oedema       |                  |                  |                  |
| subjects affected / exposed | 4 / 19 (21.05%)  | 2 / 18 (11.11%)  | 0 / 18 (0.00%)   |
| occurrences (all)           | 4                | 2                | 0                |
| Injection site pain         |                  |                  |                  |
| subjects affected / exposed | 5 / 19 (26.32%)  | 10 / 18 (55.56%) | 12 / 18 (66.67%) |
| occurrences (all)           | 5                | 10               | 12               |
| Injection site pruritus     |                  |                  |                  |
| subjects affected / exposed | 0 / 19 (0.00%)   | 0 / 18 (0.00%)   | 1 / 18 (5.56%)   |
| occurrences (all)           | 0                | 0                | 1                |
| Injection site rash         |                  |                  |                  |
| subjects affected / exposed | 0 / 19 (0.00%)   | 1 / 18 (5.56%)   | 0 / 18 (0.00%)   |
| occurrences (all)           | 0                | 1                | 0                |
| Injection site reaction     |                  |                  |                  |
| subjects affected / exposed | 10 / 19 (52.63%) | 3 / 18 (16.67%)  | 2 / 18 (11.11%)  |
| occurrences (all)           | 10               | 3                | 2                |
| Injection site swelling     |                  |                  |                  |
| subjects affected / exposed | 0 / 19 (0.00%)   | 1 / 18 (5.56%)   | 0 / 18 (0.00%)   |
| occurrences (all)           | 0                | 1                | 0                |
| Malaise                     |                  |                  |                  |
| subjects affected / exposed | 0 / 19 (0.00%)   | 2 / 18 (11.11%)  | 0 / 18 (0.00%)   |
| occurrences (all)           | 0                | 2                | 0                |
| Mucosal inflammation        |                  |                  |                  |
| subjects affected / exposed | 2 / 19 (10.53%)  | 0 / 18 (0.00%)   | 0 / 18 (0.00%)   |
| occurrences (all)           | 2                | 0                | 0                |
| Oedema                      |                  |                  |                  |
| subjects affected / exposed | 1 / 19 (5.26%)   | 0 / 18 (0.00%)   | 0 / 18 (0.00%)   |
| occurrences (all)           | 1                | 0                | 0                |
| Oedema peripheral           |                  |                  |                  |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 2 / 19 (10.53%) | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                               | 2               | 0               | 0               |
| Pain  |                 |                 |                 |
| subjects affected / exposed                     | 2 / 19 (10.53%) | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                               | 2               | 0               | 0               |
| Pyrexia   |                 |                 |                 |
| subjects affected / exposed                     | 7 / 19 (36.84%) | 6 / 18 (33.33%) | 5 / 18 (27.78%) |
| occurrences (all)                               | 7               | 6               | 5               |
| Sense of oppression                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 1 / 18 (5.56%)  |
| occurrences (all)                               | 0               | 0               | 1               |
| Respiratory, thoracic and mediastinal disorders |                 |                 |                 |
| Asthma  |                 |                 |                 |
| subjects affected / exposed                     | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                               | 1               | 0               | 0               |
| Bronchial haemorrhage                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                               | 0               | 0               | 0               |
| Bronchitis chronic                              |                 |                 |                 |
| subjects affected / exposed                     | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                               | 1               | 0               | 0               |
| Cough   |                 |                 |                 |
| subjects affected / exposed                     | 2 / 19 (10.53%) | 3 / 18 (16.67%) | 2 / 18 (11.11%) |
| occurrences (all)                               | 2               | 3               | 2               |
| Dysphonia                                       |                 |                 |                 |
| subjects affected / exposed                     | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                               | 1               | 0               | 0               |
| Dyspnoea  |                 |                 |                 |
| subjects affected / exposed                     | 3 / 19 (15.79%) | 1 / 18 (5.56%)  | 1 / 18 (5.56%)  |
| occurrences (all)                               | 3               | 1               | 1               |
| Epistaxis                                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 19 (0.00%)  | 1 / 18 (5.56%)  | 0 / 18 (0.00%)  |
| occurrences (all)                               | 0               | 1               | 0               |
| Hiccups   |                 |                 |                 |

|                             |                 |                 |                |
|-----------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%) |
| occurrences (all)           | 1               | 0               | 0              |
| Oropharyngeal pain          |                 |                 |                |
| subjects affected / exposed | 1 / 19 (5.26%)  | 1 / 18 (5.56%)  | 0 / 18 (0.00%) |
| occurrences (all)           | 1               | 1               | 0              |
| Pleural effusion            |                 |                 |                |
| subjects affected / exposed | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 1 / 18 (5.56%) |
| occurrences (all)           | 0               | 0               | 1              |
| Pleurisy                    |                 |                 |                |
| subjects affected / exposed | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%) |
| occurrences (all)           | 0               | 0               | 0              |
| Pulmonary embolism          |                 |                 |                |
| subjects affected / exposed | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%) |
| occurrences (all)           | 1               | 0               | 0              |
| Rhinorrhoea                 |                 |                 |                |
| subjects affected / exposed | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 1 / 18 (5.56%) |
| occurrences (all)           | 0               | 0               | 1              |
| Sputum discoloured          |                 |                 |                |
| subjects affected / exposed | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 1 / 18 (5.56%) |
| occurrences (all)           | 0               | 0               | 1              |
| Psychiatric disorders       |                 |                 |                |
| Anxiety                     |                 |                 |                |
| subjects affected / exposed | 1 / 19 (5.26%)  | 2 / 18 (11.11%) | 0 / 18 (0.00%) |
| occurrences (all)           | 1               | 2               | 0              |
| Depression                  |                 |                 |                |
| subjects affected / exposed | 2 / 19 (10.53%) | 0 / 18 (0.00%)  | 0 / 18 (0.00%) |
| occurrences (all)           | 2               | 0               | 0              |
| Insomnia                    |                 |                 |                |
| subjects affected / exposed | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 1 / 18 (5.56%) |
| occurrences (all)           | 1               | 0               | 1              |
| Investigations              |                 |                 |                |
| Lymphocyte count decreased  |                 |                 |                |
| subjects affected / exposed | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 1 / 18 (5.56%) |
| occurrences (all)           | 0               | 0               | 1              |
| Urine output decreased      |                 |                 |                |

|  |                      |                     |                     |
|--|----------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                             | 2 / 19 (10.53%)<br>2 | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 |
| Weight decreased<br>subjects affected / exposed<br>occurrences (all)         | 0 / 19 (0.00%)<br>0  | 0 / 18 (0.00%)<br>0 | 1 / 18 (5.56%)<br>1 |
| Weight increased<br>subjects affected / exposed<br>occurrences (all)         | 0 / 19 (0.00%)<br>0  | 1 / 18 (5.56%)<br>1 | 0 / 18 (0.00%)<br>0 |
| Injury, poisoning and procedural complications                               |                      |                     |                     |
| Concussion<br>subjects affected / exposed<br>occurrences (all)               | 1 / 19 (5.26%)<br>1  | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 |
| Contusion<br>subjects affected / exposed<br>occurrences (all)                | 0 / 19 (0.00%)<br>0  | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 |
| Radiation pneumonitis<br>subjects affected / exposed<br>occurrences (all)    | 0 / 19 (0.00%)<br>0  | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 |
| Wound<br>subjects affected / exposed<br>occurrences (all)                    | 1 / 19 (5.26%)<br>1  | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 |
| Cardiac disorders  |                      |                     |                     |
| Cardiac failure<br>subjects affected / exposed<br>occurrences (all)          | 0 / 19 (0.00%)<br>0  | 0 / 18 (0.00%)<br>0 | 1 / 18 (5.56%)<br>1 |
| Cardiac failure acute<br>subjects affected / exposed<br>occurrences (all)    | 0 / 19 (0.00%)<br>0  | 0 / 18 (0.00%)<br>0 | 1 / 18 (5.56%)<br>1 |
| Tachycardia<br>subjects affected / exposed<br>occurrences (all)              | 1 / 19 (5.26%)<br>1  | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 |
| Nervous system disorders   |                      |                     |                     |
| Cervicobrachial syndrome<br>subjects affected / exposed<br>occurrences (all) | 0 / 19 (0.00%)<br>0  | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 |
| Dizziness  |                      |                     |                     |

|                                      |                 |                 |                 |
|--------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed          | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 2 / 18 (11.11%) |
| occurrences (all)                    | 0               | 0               | 2               |
| Dysaesthesia                         |                 |                 |                 |
| subjects affected / exposed          | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                    | 0               | 0               | 0               |
| Headache                             |                 |                 |                 |
| subjects affected / exposed          | 4 / 19 (21.05%) | 5 / 18 (27.78%) | 2 / 18 (11.11%) |
| occurrences (all)                    | 4               | 5               | 2               |
| Intercostal neuralgia                |                 |                 |                 |
| subjects affected / exposed          | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                    | 0               | 0               | 0               |
| Nervous system disorder              |                 |                 |                 |
| subjects affected / exposed          | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 1 / 18 (5.56%)  |
| occurrences (all)                    | 0               | 0               | 1               |
| Neuropathy peripheral                |                 |                 |                 |
| subjects affected / exposed          | 0 / 19 (0.00%)  | 3 / 18 (16.67%) | 0 / 18 (0.00%)  |
| occurrences (all)                    | 0               | 3               | 0               |
| Paraesthesia                         |                 |                 |                 |
| subjects affected / exposed          | 1 / 19 (5.26%)  | 3 / 18 (16.67%) | 0 / 18 (0.00%)  |
| occurrences (all)                    | 1               | 3               | 0               |
| Peripheral sensory neuropathy        |                 |                 |                 |
| subjects affected / exposed          | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                    | 1               | 0               | 0               |
| Polyneuropathy                       |                 |                 |                 |
| subjects affected / exposed          | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                    | 1               | 0               | 0               |
| Sinus headache                       |                 |                 |                 |
| subjects affected / exposed          | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                    | 0               | 0               | 0               |
| Somnolence                           |                 |                 |                 |
| subjects affected / exposed          | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                    | 1               | 0               | 0               |
| Tremor                               |                 |                 |                 |
| subjects affected / exposed          | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                    | 1               | 0               | 0               |
| Blood and lymphatic system disorders |                 |                 |                 |

|                             |                 |                |                 |
|-----------------------------|-----------------|----------------|-----------------|
| Anaemia                     |                 |                |                 |
| subjects affected / exposed | 6 / 19 (31.58%) | 0 / 18 (0.00%) | 0 / 18 (0.00%)  |
| occurrences (all)           | 6               | 0              | 0               |
| Febrile neutropenia         |                 |                |                 |
| subjects affected / exposed | 5 / 19 (26.32%) | 0 / 18 (0.00%) | 0 / 18 (0.00%)  |
| occurrences (all)           | 5               | 0              | 0               |
| Iron deficiency anaemia     |                 |                |                 |
| subjects affected / exposed | 1 / 19 (5.26%)  | 0 / 18 (0.00%) | 0 / 18 (0.00%)  |
| occurrences (all)           | 1               | 0              | 0               |
| Leukopenia                  |                 |                |                 |
| subjects affected / exposed | 1 / 19 (5.26%)  | 0 / 18 (0.00%) | 0 / 18 (0.00%)  |
| occurrences (all)           | 1               | 0              | 0               |
| Monocytosis                 |                 |                |                 |
| subjects affected / exposed | 1 / 19 (5.26%)  | 0 / 18 (0.00%) | 0 / 18 (0.00%)  |
| occurrences (all)           | 1               | 0              | 0               |
| Neutropenia                 |                 |                |                 |
| subjects affected / exposed | 7 / 19 (36.84%) | 0 / 18 (0.00%) | 0 / 18 (0.00%)  |
| occurrences (all)           | 7               | 0              | 0               |
| Ear and labyrinth disorders |                 |                |                 |
| Hypoacusis                  |                 |                |                 |
| subjects affected / exposed | 1 / 19 (5.26%)  | 0 / 18 (0.00%) | 0 / 18 (0.00%)  |
| occurrences (all)           | 1               | 0              | 0               |
| Tinnitus                    |                 |                |                 |
| subjects affected / exposed | 1 / 19 (5.26%)  | 0 / 18 (0.00%) | 0 / 18 (0.00%)  |
| occurrences (all)           | 1               | 0              | 0               |
| Vertigo                     |                 |                |                 |
| subjects affected / exposed | 1 / 19 (5.26%)  | 1 / 18 (5.56%) | 0 / 18 (0.00%)  |
| occurrences (all)           | 1               | 1              | 0               |
| Eye disorders               |                 |                |                 |
| Periorbital oedema          |                 |                |                 |
| subjects affected / exposed | 0 / 19 (0.00%)  | 1 / 18 (5.56%) | 0 / 18 (0.00%)  |
| occurrences (all)           | 0               | 1              | 0               |
| Gastrointestinal disorders  |                 |                |                 |
| Abdominal discomfort        |                 |                |                 |
| subjects affected / exposed | 0 / 19 (0.00%)  | 0 / 18 (0.00%) | 2 / 18 (11.11%) |
| occurrences (all)           | 0               | 0              | 2               |
| Abdominal pain              |                 |                |                 |



|                             |                 |                 |                 |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)           | 1               | 0               | 0               |
| Abdominal pain upper        |                 |                 |                 |
| subjects affected / exposed | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)           | 1               | 0               | 0               |
| Constipation                |                 |                 |                 |
| subjects affected / exposed | 7 / 19 (36.84%) | 2 / 18 (11.11%) | 0 / 18 (0.00%)  |
| occurrences (all)           | 7               | 2               | 0               |
| Diarrhoea                   |                 |                 |                 |
| subjects affected / exposed | 5 / 19 (26.32%) | 1 / 18 (5.56%)  | 3 / 18 (16.67%) |
| occurrences (all)           | 5               | 1               | 3               |
| Flatulence                  |                 |                 |                 |
| subjects affected / exposed | 0 / 19 (0.00%)  | 1 / 18 (5.56%)  | 0 / 18 (0.00%)  |
| occurrences (all)           | 0               | 1               | 0               |
| Gastrointestinal disorder   |                 |                 |                 |
| subjects affected / exposed | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)           | 1               | 0               | 0               |
| Loose tooth                 |                 |                 |                 |
| subjects affected / exposed | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)           | 1               | 0               | 0               |
| Mouth ulceration            |                 |                 |                 |
| subjects affected / exposed | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)           | 1               | 0               | 0               |
| Nausea                      |                 |                 |                 |
| subjects affected / exposed | 7 / 19 (36.84%) | 5 / 18 (27.78%) | 1 / 18 (5.56%)  |
| occurrences (all)           | 7               | 5               | 1               |
| Regurgitation               |                 |                 |                 |
| subjects affected / exposed | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)           | 1               | 0               | 0               |
| Stomatitis                  |                 |                 |                 |
| subjects affected / exposed | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)           | 1               | 0               | 0               |
| Vomiting                    |                 |                 |                 |
| subjects affected / exposed | 6 / 19 (31.58%) | 6 / 18 (33.33%) | 2 / 18 (11.11%) |
| occurrences (all)           | 6               | 6               | 2               |
| Hepatobiliary disorders     |                 |                 |                 |

|  |                 |                |                |
|--|-----------------|----------------|----------------|
| Cholecystitis                          |                 |                |                |
| subjects affected / exposed            | 1 / 19 (5.26%)  | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all)                      | 1               | 0              | 0              |
| Hepatic failure                        |                 |                |                |
| subjects affected / exposed            | 0 / 19 (0.00%)  | 0 / 18 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all)                      | 0               | 0              | 1              |
| Skin and subcutaneous tissue disorders |                 |                |                |
| Acne                                   |                 |                |                |
| subjects affected / exposed            | 1 / 19 (5.26%)  | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all)                      | 1               | 0              | 0              |
| Alopecia                               |                 |                |                |
| subjects affected / exposed            | 4 / 19 (21.05%) | 0 / 18 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all)                      | 4               | 0              | 1              |
| Dermatitis                             |                 |                |                |
| subjects affected / exposed            | 0 / 19 (0.00%)  | 1 / 18 (5.56%) | 0 / 18 (0.00%) |
| occurrences (all)                      | 0               | 1              | 0              |
| Dry skin                               |                 |                |                |
| subjects affected / exposed            | 2 / 19 (10.53%) | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all)                      | 2               | 0              | 0              |
| Erythema                               |                 |                |                |
| subjects affected / exposed            | 0 / 19 (0.00%)  | 1 / 18 (5.56%) | 0 / 18 (0.00%) |
| occurrences (all)                      | 0               | 1              | 0              |
| Night sweats                           |                 |                |                |
| subjects affected / exposed            | 0 / 19 (0.00%)  | 0 / 18 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all)                      | 0               | 0              | 1              |
| Skin discolouration                    |                 |                |                |
| subjects affected / exposed            | 0 / 19 (0.00%)  | 1 / 18 (5.56%) | 0 / 18 (0.00%) |
| occurrences (all)                      | 0               | 1              | 0              |
| Urticaria                              |                 |                |                |
| subjects affected / exposed            | 1 / 19 (5.26%)  | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all)                      | 1               | 0              | 0              |
| Renal and urinary disorders            |                 |                |                |
| Nephrolithiasis                        |                 |                |                |
| subjects affected / exposed            | 1 / 19 (5.26%)  | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all)                      | 1               | 0              | 0              |
| Renal failure                          |                 |                |                |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                               | 1               | 0               | 0               |
| Renal pain                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 19 (0.00%)  | 1 / 18 (5.56%)  | 0 / 18 (0.00%)  |
| occurrences (all)                               | 0               | 1               | 0               |
| Musculoskeletal and connective tissue disorders |                 |                 |                 |
| Arthralgia                                      |                 |                 |                 |
| subjects affected / exposed                     | 3 / 19 (15.79%) | 0 / 18 (0.00%)  | 1 / 18 (5.56%)  |
| occurrences (all)                               | 3               | 0               | 1               |
| Back pain                                       |                 |                 |                 |
| subjects affected / exposed                     | 1 / 19 (5.26%)  | 2 / 18 (11.11%) | 3 / 18 (16.67%) |
| occurrences (all)                               | 1               | 2               | 3               |
| Bone pain                                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 19 (0.00%)  | 1 / 18 (5.56%)  | 0 / 18 (0.00%)  |
| occurrences (all)                               | 0               | 1               | 0               |
| Muscle spasms                                   |                 |                 |                 |
| subjects affected / exposed                     | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                               | 1               | 0               | 0               |
| Musculoskeletal pain                            |                 |                 |                 |
| subjects affected / exposed                     | 2 / 19 (10.53%) | 3 / 18 (16.67%) | 0 / 18 (0.00%)  |
| occurrences (all)                               | 2               | 3               | 0               |
| Myalgia   |                 |                 |                 |
| subjects affected / exposed                     | 3 / 19 (15.79%) | 1 / 18 (5.56%)  | 0 / 18 (0.00%)  |
| occurrences (all)                               | 3               | 1               | 0               |
| Osteopenia                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 19 (0.00%)  | 1 / 18 (5.56%)  | 0 / 18 (0.00%)  |
| occurrences (all)                               | 0               | 1               | 0               |
| Pain in extremity                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 19 (0.00%)  | 1 / 18 (5.56%)  | 0 / 18 (0.00%)  |
| occurrences (all)                               | 0               | 1               | 0               |
| Infections and infestations                     |                 |                 |                 |
| Bronchitis                                      |                 |                 |                 |
| subjects affected / exposed                     | 2 / 19 (10.53%) | 0 / 18 (0.00%)  | 1 / 18 (5.56%)  |
| occurrences (all)                               | 2               | 0               | 1               |
| Gingivitis                                      |                 |                 |                 |

|                                    |                 |                 |                 |
|------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed        | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                  | 1               | 0               | 0               |
| Influenza                          |                 |                 |                 |
| subjects affected / exposed        | 2 / 19 (10.53%) | 0 / 18 (0.00%)  | 1 / 18 (5.56%)  |
| occurrences (all)                  | 2               | 0               | 1               |
| Lobar pneumonia                    |                 |                 |                 |
| subjects affected / exposed        | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                  | 0               | 0               | 0               |
| Lower respiratory tract infection  |                 |                 |                 |
| subjects affected / exposed        | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 1 / 18 (5.56%)  |
| occurrences (all)                  | 0               | 0               | 1               |
| Nasopharyngitis                    |                 |                 |                 |
| subjects affected / exposed        | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 1 / 18 (5.56%)  |
| occurrences (all)                  | 1               | 0               | 1               |
| Paronychia                         |                 |                 |                 |
| subjects affected / exposed        | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                  | 1               | 0               | 0               |
| Pneumonia                          |                 |                 |                 |
| subjects affected / exposed        | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                  | 1               | 0               | 0               |
| Rhinitis                           |                 |                 |                 |
| subjects affected / exposed        | 0 / 19 (0.00%)  | 1 / 18 (5.56%)  | 1 / 18 (5.56%)  |
| occurrences (all)                  | 0               | 1               | 1               |
| Upper respiratory tract infection  |                 |                 |                 |
| subjects affected / exposed        | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 1 / 18 (5.56%)  |
| occurrences (all)                  | 0               | 0               | 1               |
| Vulvovaginal mycotic infection     |                 |                 |                 |
| subjects affected / exposed        | 0 / 19 (0.00%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                  | 0               | 0               | 0               |
| Metabolism and nutrition disorders |                 |                 |                 |
| Decreased appetite                 |                 |                 |                 |
| subjects affected / exposed        | 3 / 19 (15.79%) | 2 / 18 (11.11%) | 2 / 18 (11.11%) |
| occurrences (all)                  | 3               | 2               | 2               |
| Hypercholesterolaemia              |                 |                 |                 |
| subjects affected / exposed        | 1 / 19 (5.26%)  | 0 / 18 (0.00%)  | 0 / 18 (0.00%)  |
| occurrences (all)                  | 1               | 0               | 0               |

|                             |                 |                |                |
|-----------------------------|-----------------|----------------|----------------|
| Hypokalaemia                |                 |                |                |
| subjects affected / exposed | 1 / 19 (5.26%)  | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all)           | 1               | 0              | 0              |
| Hypomagnesaemia             |                 |                |                |
| subjects affected / exposed | 5 / 19 (26.32%) | 1 / 18 (5.56%) | 0 / 18 (0.00%) |
| occurrences (all)           | 5               | 1              | 0              |
| Iron deficiency             |                 |                |                |
| subjects affected / exposed | 2 / 19 (10.53%) | 0 / 18 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all)           | 2               | 0              | 0              |

|   |  |  |  |
|---|--|--|--|
| <b>Non-serious adverse events</b>                                   | Chemo/radiotherapy<br>-MAGE-A3 ASCI<br>Group |  |  |
| Total subjects affected by non-serious adverse events               |  |  |  |
| subjects affected / exposed   | 11 / 12 (91.67%)                             |  |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |  |  |  |
| Malignant palate neoplasm   |  |  |  |
| subjects affected / exposed   | 0 / 12 (0.00%)                               |  |  |
| occurrences (all)   | 0  |  |  |
| Vascular disorders  |  |  |  |
| Arterial disorder   |  |  |  |
| subjects affected / exposed   | 1 / 12 (8.33%)                               |  |  |
| occurrences (all)   | 1  |  |  |
| Arteriosclerosis  |  |  |  |
| subjects affected / exposed   | 0 / 12 (0.00%)                               |  |  |
| occurrences (all)   | 0  |  |  |
| Haematoma   |  |  |  |
| subjects affected / exposed   | 0 / 12 (0.00%)                               |  |  |
| occurrences (all)   | 0  |  |  |
| Hypertension  |  |  |  |
| subjects affected / exposed   | 0 / 12 (0.00%)                               |  |  |
| occurrences (all)   | 0  |  |  |
| Orthostatic hypotension   |  |  |  |
| subjects affected / exposed   | 0 / 12 (0.00%)                               |  |  |
| occurrences (all)   | 0  |  |  |
| Peripheral coldness   |  |  |  |
| subjects affected / exposed   | 0 / 12 (0.00%)                               |  |  |
| occurrences (all)   | 0  |  |  |

|  |                 |  |  |
|--|-----------------|--|--|
| Phlebitis  |                 |  |  |
| subjects affected / exposed                          | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                                    | 0               |  |  |
| Phlebitis superficial                                |                 |  |  |
| subjects affected / exposed                          | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                                    | 0               |  |  |
| Raynaud's phenomenon                                 |                 |  |  |
| subjects affected / exposed                          | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                                    | 0               |  |  |
| Thrombosis   |                 |  |  |
| subjects affected / exposed                          | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                                    | 0               |  |  |
| General disorders and administration site conditions |                 |  |  |
| Administration site pain                             |                 |  |  |
| subjects affected / exposed                          | 1 / 12 (8.33%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| Administration site reaction                         |                 |  |  |
| subjects affected / exposed                          | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                                    | 0               |  |  |
| Asthenia   |                 |  |  |
| subjects affected / exposed                          | 1 / 12 (8.33%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| Axillary pain  |                 |  |  |
| subjects affected / exposed                          | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                                    | 0               |  |  |
| Chest pain   |                 |  |  |
| subjects affected / exposed                          | 1 / 12 (8.33%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| Chills   |                 |  |  |
| subjects affected / exposed                          | 2 / 12 (16.67%) |  |  |
| occurrences (all)                                    | 2               |  |  |
| Fatigue  |                 |  |  |
| alternative assessment type: Systematic              |                 |  |  |
| subjects affected / exposed                          | 1 / 12 (8.33%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| Gait disturbance                                     |                 |  |  |

|                             |                 |  |  |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Hypothermia                 |                 |  |  |
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Influenza like illness      |                 |  |  |
| subjects affected / exposed | 2 / 12 (16.67%) |  |  |
| occurrences (all)           | 2               |  |  |
| Injection site coldness     |                 |  |  |
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Injection site erythema     |                 |  |  |
| subjects affected / exposed | 1 / 12 (8.33%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Injection site haematoma    |                 |  |  |
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Injection site inflammation |                 |  |  |
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Injection site oedema       |                 |  |  |
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Injection site pain         |                 |  |  |
| subjects affected / exposed | 3 / 12 (25.00%) |  |  |
| occurrences (all)           | 3               |  |  |
| Injection site pruritus     |                 |  |  |
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Injection site rash         |                 |  |  |
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Injection site reaction     |                 |  |  |
| subjects affected / exposed | 2 / 12 (16.67%) |  |  |
| occurrences (all)           | 2               |  |  |
| Injection site swelling     |                 |  |  |

|   |                 |  |  |
|---|-----------------|--|--|
| subjects affected / exposed                     | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Malaise   |                 |  |  |
| subjects affected / exposed                     | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Mucosal inflammation                            |                 |  |  |
| subjects affected / exposed                     | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Oedema  |                 |  |  |
| subjects affected / exposed                     | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Oedema peripheral                               |                 |  |  |
| subjects affected / exposed                     | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Pain  |                 |  |  |
| subjects affected / exposed                     | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Pyrexia   |                 |  |  |
| subjects affected / exposed                     | 4 / 12 (33.33%) |  |  |
| occurrences (all)                               | 4               |  |  |
| Sense of oppression                             |                 |  |  |
| subjects affected / exposed                     | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Respiratory, thoracic and mediastinal disorders |                 |  |  |
| Asthma  |                 |  |  |
| subjects affected / exposed                     | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Bronchial haemorrhage                           |                 |  |  |
| subjects affected / exposed                     | 1 / 12 (8.33%)  |  |  |
| occurrences (all)                               | 1               |  |  |
| Bronchitis chronic                              |                 |  |  |
| subjects affected / exposed                     | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Cough   |                 |  |  |



|                             |                 |  |  |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 2 / 12 (16.67%) |  |  |
| occurrences (all)           | 2               |  |  |
| Dysphonia                   |                 |  |  |
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Dyspnoea                    |                 |  |  |
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Epistaxis                   |                 |  |  |
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Hiccups                     |                 |  |  |
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Oropharyngeal pain          |                 |  |  |
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Pleural effusion            |                 |  |  |
| subjects affected / exposed | 1 / 12 (8.33%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Pleurisy                    |                 |  |  |
| subjects affected / exposed | 1 / 12 (8.33%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Pulmonary embolism          |                 |  |  |
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Rhinorrhoea                 |                 |  |  |
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Sputum discoloured          |                 |  |  |
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Psychiatric disorders       |                 |  |  |
| Anxiety                     |                 |  |  |
| subjects affected / exposed | 0 / 12 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |

|  |                     |  |  |
|--|---------------------|--|--|
| Depression<br>subjects affected / exposed<br>occurrences (all)   | 0 / 12 (0.00%)<br>0 |  |  |
| Insomnia<br>subjects affected / exposed<br>occurrences (all)   | 0 / 12 (0.00%)<br>0 |  |  |
| Investigations<br>Lymphocyte count decreased<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 12 (0.00%)<br>0 |  |  |
| Urine output decreased<br>subjects affected / exposed<br>occurrences (all)                                       | 0 / 12 (0.00%)<br>0 |  |  |
| Weight decreased<br>subjects affected / exposed<br>occurrences (all)   | 0 / 12 (0.00%)<br>0 |  |  |
| Weight increased<br>subjects affected / exposed<br>occurrences (all)   | 0 / 12 (0.00%)<br>0 |  |  |
| Injury, poisoning and procedural complications<br>Concussion<br>subjects affected / exposed<br>occurrences (all) | 0 / 12 (0.00%)<br>0 |  |  |
| Contusion<br>subjects affected / exposed<br>occurrences (all)  | 1 / 12 (8.33%)<br>1 |  |  |
| Radiation pneumonitis<br>subjects affected / exposed<br>occurrences (all)  | 1 / 12 (8.33%)<br>1 |  |  |
| Wound<br>subjects affected / exposed<br>occurrences (all)  | 0 / 12 (0.00%)<br>0 |  |  |
| Cardiac disorders<br>Cardiac failure<br>subjects affected / exposed<br>occurrences (all)                         | 0 / 12 (0.00%)<br>0 |  |  |

|   |                     |  |  |
|---|---------------------|--|--|
| Cardiac failure acute<br>subjects affected / exposed<br>occurrences (all)         | 0 / 12 (0.00%)<br>0 |  |  |
| Tachycardia<br>subjects affected / exposed<br>occurrences (all)                   | 0 / 12 (0.00%)<br>0 |  |  |
| Nervous system disorders  |                     |  |  |
| Cervicobrachial syndrome<br>subjects affected / exposed<br>occurrences (all)      | 1 / 12 (8.33%)<br>1 |  |  |
| Dizziness<br>subjects affected / exposed<br>occurrences (all)                     | 0 / 12 (0.00%)<br>0 |  |  |
| Dysaesthesia<br>subjects affected / exposed<br>occurrences (all)                  | 1 / 12 (8.33%)<br>1 |  |  |
| Headache<br>subjects affected / exposed<br>occurrences (all)                      | 0 / 12 (0.00%)<br>0 |  |  |
| Intercostal neuralgia<br>subjects affected / exposed<br>occurrences (all)         | 1 / 12 (8.33%)<br>1 |  |  |
| Nervous system disorder<br>subjects affected / exposed<br>occurrences (all)       | 0 / 12 (0.00%)<br>0 |  |  |
| Neuropathy peripheral<br>subjects affected / exposed<br>occurrences (all)         | 0 / 12 (0.00%)<br>0 |  |  |
| Paraesthesia<br>subjects affected / exposed<br>occurrences (all)                  | 1 / 12 (8.33%)<br>1 |  |  |
| Peripheral sensory neuropathy<br>subjects affected / exposed<br>occurrences (all) | 0 / 12 (0.00%)<br>0 |  |  |
| Polyneuropathy  |                     |  |  |

|                                      |                |  |  |
|--------------------------------------|----------------|--|--|
| subjects affected / exposed          | 0 / 12 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Sinus headache                       |                |  |  |
| subjects affected / exposed          | 1 / 12 (8.33%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Somnolence                           |                |  |  |
| subjects affected / exposed          | 1 / 12 (8.33%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Tremor                               |                |  |  |
| subjects affected / exposed          | 0 / 12 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Blood and lymphatic system disorders |                |  |  |
| Anaemia                              |                |  |  |
| subjects affected / exposed          | 0 / 12 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Febrile neutropenia                  |                |  |  |
| subjects affected / exposed          | 0 / 12 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Iron deficiency anaemia              |                |  |  |
| subjects affected / exposed          | 0 / 12 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Leukopenia                           |                |  |  |
| subjects affected / exposed          | 0 / 12 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Monocytosis                          |                |  |  |
| subjects affected / exposed          | 0 / 12 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Neutropenia                          |                |  |  |
| subjects affected / exposed          | 0 / 12 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Ear and labyrinth disorders          |                |  |  |
| Hypoacusis                           |                |  |  |
| subjects affected / exposed          | 0 / 12 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Tinnitus                             |                |  |  |

|                             |                |  |  |
|-----------------------------|----------------|--|--|
| subjects affected / exposed | 0 / 12 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Vertigo                     |                |  |  |
| subjects affected / exposed | 1 / 12 (8.33%) |  |  |
| occurrences (all)           | 1              |  |  |
| Eye disorders               |                |  |  |
| Periorbital oedema          |                |  |  |
| subjects affected / exposed | 0 / 12 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Gastrointestinal disorders  |                |  |  |
| Abdominal discomfort        |                |  |  |
| subjects affected / exposed | 0 / 12 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Abdominal pain              |                |  |  |
| subjects affected / exposed | 1 / 12 (8.33%) |  |  |
| occurrences (all)           | 1              |  |  |
| Abdominal pain upper        |                |  |  |
| subjects affected / exposed | 1 / 12 (8.33%) |  |  |
| occurrences (all)           | 1              |  |  |
| Constipation                |                |  |  |
| subjects affected / exposed | 0 / 12 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Diarrhoea                   |                |  |  |
| subjects affected / exposed | 0 / 12 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Flatulence                  |                |  |  |
| subjects affected / exposed | 0 / 12 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Gastrointestinal disorder   |                |  |  |
| subjects affected / exposed | 0 / 12 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Loose tooth                 |                |  |  |
| subjects affected / exposed | 0 / 12 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Mouth ulceration            |                |  |  |

|  |                |  |  |
|--|----------------|--|--|
| subjects affected / exposed            | 0 / 12 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Nausea                                 |                |  |  |
| subjects affected / exposed            | 1 / 12 (8.33%) |  |  |
| occurrences (all)                      | 1              |  |  |
| Regurgitation                          |                |  |  |
| subjects affected / exposed            | 0 / 12 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Stomatitis                             |                |  |  |
| subjects affected / exposed            | 0 / 12 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Vomiting                               |                |  |  |
| subjects affected / exposed            | 0 / 12 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Hepatobiliary disorders                |                |  |  |
| Cholecystitis                          |                |  |  |
| subjects affected / exposed            | 0 / 12 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Hepatic failure                        |                |  |  |
| subjects affected / exposed            | 0 / 12 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Skin and subcutaneous tissue disorders |                |  |  |
| Acne                                   |                |  |  |
| subjects affected / exposed            | 0 / 12 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Alopecia                               |                |  |  |
| subjects affected / exposed            | 0 / 12 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Dermatitis                             |                |  |  |
| subjects affected / exposed            | 0 / 12 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Dry skin                               |                |  |  |
| subjects affected / exposed            | 0 / 12 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Erythema                               |                |  |  |

|   |  |  |  |
|---|--|--|--|
| <p>subjects affected / exposed</p> <p>0 / 12 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>  |  |  |  |
| <p>Night sweats</p> <p>subjects affected / exposed</p> <p>0 / 12 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>  |  |  |  |
| <p>Skin discolouration</p> <p>subjects affected / exposed</p> <p>0 / 12 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>   |  |  |  |
| <p>Urticaria</p> <p>subjects affected / exposed</p> <p>0 / 12 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>   |  |  |  |
| <p>Renal and urinary disorders</p> <p>Nephrolithiasis</p> <p>subjects affected / exposed</p> <p>0 / 12 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Renal failure</p> <p>subjects affected / exposed</p> <p>0 / 12 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Renal pain</p> <p>subjects affected / exposed</p> <p>0 / 12 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>   |  |  |  |
| <p>Musculoskeletal and connective tissue disorders</p> <p>Arthralgia</p> <p>subjects affected / exposed</p> <p>1 / 12 (8.33%)</p> <p>occurrences (all)</p> <p>1</p> <p>Back pain</p> <p>subjects affected / exposed</p> <p>1 / 12 (8.33%)</p> <p>occurrences (all)</p> <p>1</p> <p>Bone pain</p> <p>subjects affected / exposed</p> <p>0 / 12 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Muscle spasms</p> <p>subjects affected / exposed</p> <p>0 / 12 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Musculoskeletal pain</p> |  |  |  |

|                                   |                 |  |  |
|-----------------------------------|-----------------|--|--|
| subjects affected / exposed       | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                 | 0               |  |  |
| Myalgia                           |                 |  |  |
| subjects affected / exposed       | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                 | 0               |  |  |
| Osteopenia                        |                 |  |  |
| subjects affected / exposed       | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                 | 0               |  |  |
| Pain in extremity                 |                 |  |  |
| subjects affected / exposed       | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                 | 0               |  |  |
| Infections and infestations       |                 |  |  |
| Bronchitis                        |                 |  |  |
| subjects affected / exposed       | 3 / 12 (25.00%) |  |  |
| occurrences (all)                 | 3               |  |  |
| Gingivitis                        |                 |  |  |
| subjects affected / exposed       | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                 | 0               |  |  |
| Influenza                         |                 |  |  |
| subjects affected / exposed       | 1 / 12 (8.33%)  |  |  |
| occurrences (all)                 | 1               |  |  |
| Lobar pneumonia                   |                 |  |  |
| subjects affected / exposed       | 1 / 12 (8.33%)  |  |  |
| occurrences (all)                 | 1               |  |  |
| Lower respiratory tract infection |                 |  |  |
| subjects affected / exposed       | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                 | 0               |  |  |
| Nasopharyngitis                   |                 |  |  |
| subjects affected / exposed       | 2 / 12 (16.67%) |  |  |
| occurrences (all)                 | 2               |  |  |
| Paronychia                        |                 |  |  |
| subjects affected / exposed       | 0 / 12 (0.00%)  |  |  |
| occurrences (all)                 | 0               |  |  |
| Pneumonia                         |                 |  |  |
| subjects affected / exposed       | 2 / 12 (16.67%) |  |  |
| occurrences (all)                 | 2               |  |  |



|                                    |                |  |  |
|------------------------------------|----------------|--|--|
| Rhinitis                           |                |  |  |
| subjects affected / exposed        | 0 / 12 (0.00%) |  |  |
| occurrences (all)                  | 0              |  |  |
| Upper respiratory tract infection  |                |  |  |
| subjects affected / exposed        | 0 / 12 (0.00%) |  |  |
| occurrences (all)                  | 0              |  |  |
| Vulvovaginal mycotic infection     |                |  |  |
| subjects affected / exposed        | 1 / 12 (8.33%) |  |  |
| occurrences (all)                  | 1              |  |  |
| Metabolism and nutrition disorders |                |  |  |
| Decreased appetite                 |                |  |  |
| subjects affected / exposed        | 1 / 12 (8.33%) |  |  |
| occurrences (all)                  | 1              |  |  |
| Hypercholesterolaemia              |                |  |  |
| subjects affected / exposed        | 0 / 12 (0.00%) |  |  |
| occurrences (all)                  | 0              |  |  |
| Hypokalaemia                       |                |  |  |
| subjects affected / exposed        | 0 / 12 (0.00%) |  |  |
| occurrences (all)                  | 0              |  |  |
| Hypomagnesaemia                    |                |  |  |
| subjects affected / exposed        | 0 / 12 (0.00%) |  |  |
| occurrences (all)                  | 0              |  |  |
| Iron deficiency                    |                |  |  |
| subjects affected / exposed        | 0 / 12 (0.00%) |  |  |
| occurrences (all)                  | 0              |  |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date            | Amendment   |
|-----------------|---|
| 09 March 2009   | In Amendment 1, dated 9 March 2009, the following changes were made: 1 /The patient population for Cohorts 1, 2 and 3 was modified from resected stage IB, II or IIIA to completely resected stage IA, IIB or III (with the exception of stage III N2 and N3) to allow enrolment of patients with completely resected T4 primary tumor with satellite lesions in the same lobe (stage IIIB). 2/ The recruitment period was extended to increase the feasibility of the study i.e. to facilitate enrolment and ensure that the targeted number of patients was reached. 3/The inclusion of tissue from lymph nodes as screening material was allowed to enable the screening and enrolment of patients with a less accessible primary tumor, which was especially important for patients in Cohort 4 (i.e. patients with unresectable stage III tumors, for whom no surgical material was obtained). 4/The time window between surgery/previous therapy and the first ASCI administration was extended for 2 cohorts i.e. 4 to 12 weeks for patients in Cohort 1, and 2 to 6 weeks for patients in Cohort 4. 5/The replacement of patients from Cohort 1 who withdrew because of an adverse event resulting from chemotherapy before the first ASCI administration was permitted. 6/ The sections regarding immunological assays were updated to include extension of the immune response analysis with assessment of anti-Cytosine Phosphate Guanosine oligodeoxynucleotide (CpG) antibody responses and analysis of antigen spreading. |
| 06 January 2011 | In Protocol Amendment 2, dated 6 January 2011, the following changes were made: 1/The description of the study product was changed to the 2-vial presentation, as the 3-vial presentation was no longer manufactured. 2/The handling instructions were updated to increase the allowed delay and allowed temperature between reconstitution of the study product and administration. 3/ In addition, the sections on the storage of the study product and study contact for reporting SAEs were also updated.   |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date           | Interruption  | Restart date |
|----------------|---|--------------|
| 05 August 2013 | The study was terminated early on 5 August 2008, due to slow recruitment and difficulties to achieve the required patient population in the cohort 4. Enrolment and study procedures for patients enrolled in the other 3 groups took place as per planned. | -            |

Notes:

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

An analysis for anti-CpG immunogenicity was planned but not performed as the related test remains under development & it is not foreseen by GSK Biologicals that this immunogenicity has association with clinical benefit.

Notes:

